CA2494115A1

CA2494115A1 - Mutants of ige proteins and uses thereof

Info

Publication number: CA2494115A1
Application number: CA002494115A
Authority: CA
Inventors: Theodore S. Jardetzky; Beth A. Wurzburg
Original assignee: Northwestern University
Current assignee: Individual
Priority date: 2002-08-01
Filing date: 2003-08-01
Publication date: 2004-02-12
Also published as: WO2004013158A3; EP1527099A2; WO2004013158A2; JP2006500923A; AU2003278702A1

Abstract

The present invention generally relates to mutant IgE proteins. Specifically, the present invention relates to modified IgE proteins that have reduced flexibility in their heavy chains in comparison to unmodified IgE proteins and are, as a result, constrained in a particular conformational state. The present invention also relates to three-dimensional models of IgE
glycosylation mutants. The present invention also relates to the use of proteins of the instant invention to produce and isolate compounds that will inhibit the binding of IgE protein to Fc.epsilon.Rl or Fc.epsilon.Rl.alpha..
Also included in the present invention are nucleic acid molecules encoding proteins of the instant invention. Also included are compounds which inhibit the binding of IgE to its receptor. The present invention also includes therapeutic compositions and kits comprising proteins and/or compounds of the instant invention as well as methods of treating an animal using such compositions and kits.

Description

MUTANTS OF IgE PROTEINS AND USES THEREOF
FIELD OF THE INVENTION
The present invention relates to mutant immunoglobulin epsilon (IgE) proteins and three-dimensional models of such proteins. The invention also relates to the use of the mutant proteins to identify compounds useful in the prevention and treatment of allergy and the regulation of immune responses in an animal.
BACKGROUND OF THE INVENTION
Antibody Fc-receptors (FcRs) play an important role in the immune response by coupling the specificity of secreted antibodies to a variety of cells of the immune system.
A number of cell types, including macrophages, mast cells, eosinophils, and basophils, express membrane-bound FcRs on their surfaces. The binding of allergen-bound antibodies to FcRs provides antigen-specificity to these cells, which upon activation release further cell-specific mediators of the immune response, such as interleukins, initiators of inflammation, leukotrienes, prostaglandins, histamines, or cytotoxic proteins.
The adoptive specificity of the FcRs allows a combinatorial approach to pathogen elimination, by coupling the diversity of antibody antigen-recognition sites to the variety of cell-types expressing these receptors.
FcR-initiated mechanisms are important in normal immunity to infectious disease as well as in allergies, antibody-mediated tumor recognition, autoimmune diseases, and other diseases in which immune responses are abnormal (i.e., not properly regulated).
Recent experiments with transgenic mice have demonstrated that the FcRs control key steps in the immune response, including antibody-directed cellular cytotoxicity and inflammatory cascades associated with the formation of immune complexes; see, for example, Ravetch et al., 1998, Ayanu Rev Imfnunolo 16, 421-432. Receptors that bind IgG
(FcgRI, FegRII, and FcgRIII, known collectively as FcgRs) mediate a variety of inflammatory reactions, regulate B-cell activation, and also trigger hypersensitivity reactions. The high affinity Fc epsilon receptor (also known as the IgE
receptor or FceRI) is associated with the activation of mast cells and the triggering of allergic reactions and anaphylactic shocle. Knockout mice for the FceRI alpha chain (FceRIa) are unable to mount IgE-mediated anaphylaxis (see for example, Dombrowicz et al., 1993, Cell 75, 969-976), although FcgRs are still able to activate mast cells (see, for example, Dombrowicz et al., 1997, J. Cli~z. Invest. 99, 915-925; Oettgen et al., 1994, Nature 370, 367-370). FceRI has also been shown to trigger anti-parasitic reactions from platelets and eosinophils as well as deliver antigen into the MHC class II presentation pathway for the activation of T cells; see, for example, Gounni et al., 1994, Nature 367, 183-186; Joseph et al., 1997, Eur~. J. Inzzzzunol. 27, 2212-2218; Maurer et al., 1998, J.
Iznzzzunol. 161, 2731-2739. The beta subunit of FceRI has been associated with asthma in genetic studies; see, for example, Hill et al., 1996, Huzn. Mol. Genet. 5, 959-962; Hill et al., 1995, Bnzj 311, 776-779; Kim et al., 1998, Curr. Opin. Pulse. Med. 4, 46-48; Mao et al., 1998, Clin.
Genet. 53, 54-56; Shirakawa et al., 1994, Nat. Genet. 7, 125-129. A
significant fraction of the population (~20%) may be affected by allergies, and this century has seen a substantial increase in asthma. Since IgE binding to FceRI is a requisite event in the reaction to different allergens, therapeutic strategies aimed at inhibiting FceRI/IgE
interactions could provide a useful treatment for these diseases. For example, monoclonal antibodies that target IgE and block receptor binding have shown therapeutic potential;
see, for example, Heusser et al., 1997, Curz-. Opin. Inzmunol. 9, 805-813.
FceRI is found as a tetrameric (abg2) or trimeric (age) membrane bound receptor on the surface of mast cells, basophils, eosinophils, langerhans cells and platelets. The alpha chain, also referred to as FceRIa, of FceRI binds IgE molecules with high affinity (KA of about 10~ to 101° moles/liter (M)), and can be secreted as a 172-amino acid soluble, IgE-binding fragment by the introduction of a stop codon before the single C-terminal transmembrane anchor; see, for example, Blank et a1.,1991, E. J.
Biol. Clzenz.
266, 2639-2646, which describes the secretion of a soluble IgE-binding fragment of 172 amino acids. The extracellular domains of the human FceRIa protein belong to the immunoglobulin (Ig) superfamily and contain seven N-linked glycosylation sites.
Glycosylation of FceRIa affects the secretion and stability of the receptor, but is not required for IgE-binding; see, for example, LaCroix et al., 1993, Mol.
Inzfnunol. 3~, 321-330; Letourneur et a1.,1995, J. Biol. Clzenz. 270, 8249-8256; Robertson, 1993, J. Biol.
Chenz.. 268, 12736-12743; Scarselli et al., 1993, FEBS Lett 329, 223-226. The beta and gamma chains of FceRI are signal transduction modules.
Prior investigators have disclosed the nucleic acid sequence encoding the proteins for human FceRIa; see, for example, U.S. Patent No. 4,962,035, by Leder, issued October 9, 1990; U.S. Patent No. 5,639,660, by Kinet et al., issued June 17, 1997;
Kochan et al., 1988, Nucleic Acids Res. 16, 3584; Shimizu et al., 1988, Proc. Natl. Acad.
Sci. USA 85, 1907-1911; and Pang et al., 1993, J. Iznmunol. 151, 6166-6174. Nucleic acid sequences have also been reported for nucleic acid molecules encoding the human FceRI
beta and gamma chains; see, respectively, Kuster et al., 1992, J. Biol. CIZem. 267, 12782-12787;
Kuster et al., 1990, J. Biol. Claem. 265, 6448-6452. Nucleic acid sequences have also been reported for nucleic acid molecules encoding canine FceRIa, murine FceRIa, rat FceRIa, feline FceRIa and equine FceRIa proteins; see, respectively, GenBankTM
accession number D16413; Swiss-Prot accession number P20489 (represents encoded protein sequence); GenBank accession number J03606; PCT Publication No. WO
98/27208, by Frank et al., published June 25, 1998, referred to herein as WO
98/27208;
and PCT Publication No. WO 99/38974, by Weber et al., published August 5, 1999, referred to herein as WO 99/38974. In addition, methods to detect IgE
antibodies using a FceRIa protein have been reported in PCT Publication No. WO 98/23964, by Frank et al., published June 4, 1998, referred to herein as WO 98/23964; WO 98/27208, ibid.;
PCT
Publication No. WO 98/45707, by Frank et al., published October 15, 1998, referred to herein as WO 98/45707; and WO 99/38974, ibid.. WO 98/23964, WO 98/27208, WO
98/45707 and WO 99/38974 are each incorporated by reference herein in its entirety.
IgE shares the general overall structure common to all immunoglobulin molecules in that it is composed of four polypeptide chains: two identical heavy chains (H chains) and two identical light chains (L chains) (reviewed in Immunobiology: The Immune System in Health and Disease, Janeway and Travers, 1996, Garland Publishing Inc. New York which is incorporated by reference in its entirety). The two heavy chains, which have a molecular weight of approximately 65 kDa each in their unglycosylated form, are linked by disulfide bonds. Each heavy chain is further linked to a light chain, each light chain having a molecular weight of approximately 25 kDa, resulting in the final, four chain molecule. Both the heavy and light chains contain distinct sequence domains. The light chains contain two domains, a variable domain (referred to as VL), with the sequence in this region varying between different antibodies of the same isotype, and a constant domain (referred to as CL), with the sequence in this region remaining constant between different antibodies of the same isotype. The number of sequence domains in the heavy chains varies between the different isotypes. The heavy chain polypeptide of IgE has five sequence domains consisting of one variable sequence domain (referred to as VH), and four constant sequence domains (referred to as Cel-Ce4). It is the VL and VH
domains which are involved in antigen recognition whereas the constant domains of the heavy chains impart the distinctive functional properties (e.g., receptor binding) of an immunoglobulin class to the molecule and determine to which of the five main immunoglobulin classes the molecule belongs.
In addition to the heavy and light protein components, all immunoglobulins also contain significant amounts of carbohydrate in the form of simple and complex side chains covalently linked to amino acids in the polypeptide chains. The carbohydrate side chains are usually attached via an N-glycosidic linkage, although O-glycosidic linkages have been observed. In general, carbohydrate side chains are attached to the protein portion of the molecule via linkages located in one of the constant domains of the heavy chain although exceptions to this rule have been seen. The number of glycosidic linkages varies between and within immunoglobulin types, although in general, IgE is believed to have an average of 5 oligosaccharides per complete immunoglobulin molecule IgE antibodies interact with the cellular receptors FceRIa and FceRII (CD23) through amino acid sequences present in the constant domains of the heavy chains. There have been several reports of the use of mutagenesis and swapping techniques to attempt to identify amino acids of either FceRIa or IgE involved in the binding of (i.e., interaction between) those respective proteins, reports attempting to model FceRIa proteins based on homology to other Ig-superfamily members, and reports that identify compounds that apparently inhibit such binding; see, for example, Cook et al., 1997, Bioclzewistf~y 36, l 5579-15588; Hulett et al., 1994, J. Biol. Clzerrz. 269, 15287-15293; Hulett et al., 1995, J.
Biol. Cltem 270, 21188-21194; Mallamaci et al., 1993, J. Biol. Clzezn. 265, 22076-22083;
Robertson, 1993, ibid.; Scarselli et al., 1993, ibid. McDonnell et al., 1997, Biochem. Soc.
Tran.s. 25, 387-392; McDonnell et al., 1996, Nat. Struc. Biol. 3, 419-426; PCT
Publication No. WO 97/40033, by Cheng et al., published October 30, 1997; U.S.
Patent No. 5,180,805, by Gould et al., issued January 19, 1993; U.S. Patent No.
5,693,758, by Gould et al., issued December 2, 1997; PCT Publication No. WO 96/01643, by Gould et al., published January 25, 1996; PCT Publication No. WO 95/14779, by Gould et al., published June l, 1995. Recent crystallographic examination of the individual molecules as well as .the IgE/FceRIa complex has elucidated the specific amino acids involved in the interaction between IgE and FceRIa; see, for example, PCT Publication No. WO
00/26246, Jardetzky et al., published May 11, 2000; U.S. Patent Publication No.
20030003502-A1, Jardetzky et al., published January 2, 2003; PCT Publication No. WO
01/69253 A3, Jardetzky et al., published September 20, 2001; U.S. Patent Publication No.

20010039479, Jardetzky et al., published November 8, 2001; and PCT Publication No.
WO 01/68861 A3, Jardetzky et al., published September 20, 2001, each of which is incorporated herein by reference in its entirety. The three-dimensional models generated by these studies have shown that the binding of FceRIa to IgE is mediated by interactions of amino acids in FceRIa with amino acids in the Ce2/Ce3 linleer region (also referred to as the flexible linker region) and in the Ce3 domains of the IgE heavy chain.
Furthermore, the 3-dimensional models of IgE demonstrate that the heavy chains of IgE
are flexible and can adopt at least two unique conformations, a closed conformation and an open conformation. The two conformations can be distinguished, in part, by the relative spatial orientation of the Ce3 domains which are fuuther apart in the open conformation and closer together in the closed conformation. In the closed conformation, the Ce3-Ce4 interdomain angle is more acute than that observed between homologous IgG-Fc domains (Deisenhofer et al., 1976; Harris et al., 1999) or in the FceRI-bound IgE-Fc (open conformation, Garman et al., 2000). Additionally, both the relative disposition of the two Ce3 domains with respect to each other and to the Ce4 domains is altered. In the closed structure, the IgE-Fc Ce3 domains are closer together and slightly rotated with respect to each other. In addition, the distance between the first residue (the N-terminal amino acid) of the Ce3 A strands is only about 13 A to about 22 A. The distance increases to 23 A in the open conformation of IgE-Fc, which is similar to the observed between the Cy domains in the IgG2a-Fc (Harris et al., 1997). In the change between the open and closed conformations, the top of each Ce3 domain moves about 10 A towards the other Ce3 domain across the diner axis and 8 ~ towards the Ce4 domain of the same chain.
Studies of the IgE/FceRIa complex have revealed the IgE-Fc molecule is in the open conformation when bound to FceRIa. The large conformational change of the IgE-Fc structure reorients loops in the Ce3 domain that interact with the high affinity receptor, FceRI. The large movement of the FceRI-binding loops suggests that they would be poorly positioned in the closed IgE-Fc structure to interact with the receptor. In the open form, the receptor-binding loops are exposed and the binding residues display a large concave surface that is available to interact with FceRIa. Based in part on these data, it is predicted that if IgE molecules are forced to adopt the closed configuration, due to binding of a compound for example, these closed IgE molecules would be unable to bind to FcsRIa. Further, using these data, it is possible to design tools (e.g.
mutant proteins) useful for the production of compounds that bind IgE, locking it in the closed conformation thereby preventing it from binding to its receptor.
While studies to date have provided information on the structure of IgE and FceRIa as well as the nature of their interaction, the need remains for specific tools useful for the discovery and production of compounds with which to treat and diagnose allergy and to regulate immune responses. Also needed are safe and efficacious compounds to prevent or treat allergy and to regulate other immune responses in an animal.
SUMMARY OF THE INVENTION
The present invention generally relates to mutant, IgE heavy chain proteins, IgE
proteins comprising mutant IgEH~ proteins and 3-dimensional models of such mutant IgE
proteins. Specifically, the present invention relates to mutant IgE proteins that have reduced flexibility in their heavy chains in comparison to the native molecule and are, as a result, constrained in a particular conformational state. The present invention also relates to 3-dimensional models of IgE glycosylation mutants. IgE and IgEHC
mutants can be used, for example, to isolate or produce compounds that regulate the IgE-mediated immune response in an animal. The present invention also relates to the use of mutant IgEHC and mutant IgE proteins of the instant invention to produce and isolate compounds that will inhibit the binding of IgE to FceRI or FceRIa. Included in the present invention are nucleic acid molecules encoding proteins of the instant invention as well as cells and recombinant viruses comprising such nucleic acid molecules. Also included are compounds which inhibit the binding of IgE to FceRI or FceRIa. The present invention also includes therapeutic compositions and kits comprising proteins and/or compounds of the instant invention as well as methods of treating an animal using such compositions and kits. Accordingly, the present invention builds on the teaching of PCT
Publication No. WO 00/26246, Jardetzky et al., published May 11, 2000; U.S. Patent Publication No.
20030003502-A1, Jardetzky et al., published January 2, 2003; PCT Publication No. WO
01/69253 A3, Jardetzky et al., published September 20, 2001; U.S. Patent Publication No.
20010039479, Jardetzky et al., published November 8, 2001; and PCT Publication No.
WO 01/68861 A3, Jardetzky et al., published September 20, 2001.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig.l shows a comparison of the inter-chain and inter-residue distance in the open and closed conformations of IgE-Fc. Fig. la shows a side view of the Ce3 and Ce4 domains in the closed conformation. Fig. 1b shows a top view of the Ce3 domains in the closed conformation. The solid line indicates the 13 A gap between the N-terminal amino acids (residues 336) of each chain. Fig. 1b shows a side view of the Ce3 and Ce4 domains in the open conformation. Fig. 1d shows a top view of the Ce3 domains in the open conformation. The solid line indicates the 23.5 A gap between the N-terminal amino acids (residues 336) of each chain.
Fig. 2 shows a schematic representation of the open and closed IgE
conformations, highlighting the potential disulfide bonds that could be formed by the cysteine residues created in the IgEHC mutants (e.g. disulfide bonds at amino acid positions 329 and 335 are shown) Fig. 2a shows the Ce4 domain and residues 329-336 of the Ce3 domain in the closed conformation. The solid line represents a disulfide bond between residues 335 of each heavy chain. Fig. 2b shows the Ce4 domain and residues 329-336 of the Ce3 domain in the open conformation. The solid line represents a disulfide bond between residues 329 of each heavy chain.
Fig. 3 shows a western blot of the IgEHC cysteine mutant proteins separated by PAGe under reducing and non-reducing conditions. Numbers above each lane indicate the amino acid residue in IgEHC changed to a cysteine with the potential to form an interchain disulfide bond. The position of protein monomers and diners are indicated by the arrows on the left side of the figure. Fig. 3a shows the proteins exist in both monomeric and dimeric forms when analyzed under non-reducing conditions. Fig.
3b shows that when the IgE-Fc proteins are subjected to reducing conditions, they all exist in the monomeric form.
DETAILED DESCRIPTION OF THE INVENTION
The present invention generally relates to mutant IgE proteins, mutant IgEHc proteins and 3-dimensional models of such mutant IgE proteins. In describing the present invention, certain terms used herein are defined as follows:
As used herein, the term "a" or "an" entity refers to one or more of that entity; for example, a protein refers to one or more proteins or at least one protein; as another example, a nucleic acid molecule refers to one or more nucleic acid molecules or at least one nucleic acid molecule. As such, the terms "a" or "an", "one or more", and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably herein.
As used herein, the terms "IgE heavy chain", "IgEHC" and "IgEHC protein" can be used interchangeably and refer to a protein from any animal that comprises an IgE Fc receptor binding site and, as such, contains at least a portion of Ce3, with or without at least a portion of Ce4. An IgEH~ protein can be full-length immunoglobulin epsilon (IgE) heavy chain, a full-length Fc region of an IgE heavy chain, a fragment of an IgE Fc region that binds to FceRI or FceRIa, or any protein comprising a fragment of an IgE Fc region that binds to FceRI or FceRIa.
As used herein, the terms "IgECe3", "Ce3" and "Ce3 domain" can be used interchangeably and refer to the third constant region domain of the full length IgE heavy chain protein.
As used herein, the term "IgECe4", "Ce4" and "Ce4 domain" can be used interchangeably and refer to the fourth constant region domain of the full length IgE
heavy chain protein.
As used herein, the term "IgECe3/Ce4" refers to a protein comprising at least a portion of IgECe3 and at least a portion of IgECe4.
As used herein, the term "Ce2/Ce3 linker region" refers to the amino acid segment between the second and third constant domains.
As used herein, the term "IgE Fc region" refers to the region of the IgE heavy chain consisting of the second, third and fourth constant domains, Ce2, Ce3 and Ce4.
As used herein, the term "IgE protein" refers to a molecule comprising at least one or more IgEH~ proteins, either alone or in combination with one or more IgE
light chains.
One example of an IgE protein is an IgE antibody comprising two heavy chains and two light chains, with another example being an IgEH~ dimer.
As used herein, the term "unmodified", as applied to IgE proteins, refers to IgE
proteins having FceRI or FceRIa binding activity identical to the FceRI or FceRIa binding activity of an IgE protein comprising an IgEH~ that comprises the amino acid sequence of SEQ ID NO:11. As applied to IgEH~'s and related nucleic acid molecules (i.e. nucleic acid molecules encoding such IgEH~'s), the term "unmodified"
refers to IgEH~'s and related nucleic acid molecules having functional characteristics identical to those possessed by an IgEH~ or a related nucleic acid molecule comprising amino acid sequence SEQ ID N0:11 or nucleotide sequence SEQ ID N0:10, respectively.
As used herein, the term "mutant" refers to IgE proteins, IgEH~ proteins and related nucleic acid molecules having sequences similar to unmodified IgE
proteins, IgEHC proteins and related nucleic acid molecules but that differ functionally from their unmodified counterparts. Specifically, mutant IgE proteins, mutant IgEHC's and related nucleic acid molecules (i.e. nucleic acid molecules encoding such IgEH~'s) do not bind FceRI in the same manner as an unmodified counterpart. Mutants may be isolated from nature or may be created as a result of manipulation.
As used herein, the term "isolated" refers to IgE proteins, IgEH~ proteins and related nucleic acid molecules that have been removed from their natural milieu. As such, the term "isolated" does not necessarily reflect the extent to which the IgE proteins, IgEH~ proteins and related nucleic acid molecules have been purified. An isolated IgE
protein, IgEH~ protein or related nucleic acid molecules can be obtained from its natural source or it can be produced using recombinant technology and/or through the use of chemical synthesis or modification.
As used herein, the term "closed conformation" refers to the 3-dimensional conformation of an IgE protein in which the constant domains of the IgEH~
proteins are oriented in such a way as to prevent binding of the IgE protein to an FceRI or FceRIa.
IgE proteins in a closed conformation have IgEH~ proteins in which the N-terminal amino acid of the Ce3 domains are less than 23 angstroms (A) apart.
As used herein, the term "open conformation" refers to a 3-dimensional conformation of an IgE protein in which the constant domains of the IgEH~
proteins are oriented in such a way as to allow binding of the IgE molecule to a FceRI or FceRIa. An IgE protein in the open conformation is one in which the N-terminal amino acid of the Cs3 domains are at least 23 A apart.
As used herein, the term "spatial mobility" refers to the ability of the IgEHc proteins to move or shift their position relative to one another and/or the rest of the IgE
protein.
As used herein, the teen "reduced spatial mobility" refers to an IgE protein that is in one conformation, either open or closed, and in which the motion of the IgEHC's are restricted so that the IgE protein is unable to adopt the alternative conformation. For example, an IgE in the closed conformation having reduced spatial mobility is unable to alter it's conformation so that the N-terminal amino acids of the Ce3 domains are at least 23A apart. Similarly, the term "constrained" refers to an IgE that is in one conformation, either open or closed, and is unable to adopt the alternative conformation.
As used herein, the term "IgE open form mutants" (IgEofr") refers to mutant IgE
proteins that are constrained in the open conformation and have reduced spatial mobility such that they are unable to adopt the closed conformation.

As used herein, the term "IgE closed form mutants" (IgE~f,T,) refers to mutant IgE
proteins that are constrained in the closed conformation and have reduced spatial mobility StlCh that they are unable to adopt the open conformation.
As used herein, the term "IgE glycosylation mutant" (IgE~",) refers to mutant IgE
proteins in which the amino acid sequence of one or more N-linked glycosylation sites has been altered so that the site is no longer an N-linked glycosylation site (i.e. the mutated site can no longer be glycosylated by the N-linked glycosylation method).
As used herein, the term "extracellular domain of a FceRIa protein" is the portion of the FceRI alpha chain that is exposed to the environment outside the cell and that binds to the Fc domain of an IgE antibody. Such an FceRIa extracellular domain can be (a) a complete extracellular domain which is a domain that extends from the first amino acid of a mature FcsRI alpha chain through the last amino acid prior to the start of the transmembrane region or an extracellular domain that is functionally equivalent, in that such a domain includes D1 and D2 domains, and displays a similar affinity for the IgE
antibody to which such an FceRIa protein naturally binds or (b) a fragment of any of the extracellular domains of (a), wherein the fragment retains its ability to bind to the Fc domain of an IgE antibody.
In one aspect, the present invention provides isolated mutant IgE proteins comprising IgEH~'s having reduced spatial mobility in comparison to the spatial mobility of the IgEH~'s in an unmodified IgE protein. Suitable mutant IgE proteins are those in which the spatial mobilities of the IgEH~ Ce3 and Ce4 domains within the IgE
protein have been restricted due to modification of the IgEH~'s. Previous crystallographic analysis of the umnodified IgE protein Ce3 and Ce4 domains has demonstrated these domains can move within the IgE protein causing the IgE protein to adopt one of at least two conformations: an open conformation or a closed conformation. In the closed conformation, the N-terminal amino acid residues of the Ce3 domains of the two heavy chains, which correspond to the amino acid in position 9 of SEQ ID N0:11, which itself corresponds to position 336 of the full-length human IgE heavy chain protein, have an inter-residue distance of about 13 A whereas in the open conformation, the tvo Ce3 domain N-terminal amino acid residues are positioned so that they have an inter-residue distance of at least 23 A. The IgE protein is in the open conformation when bound to FceRIa and, based on the structural data, it is predicted that IgE proteins in the closed conformation would be unable to bind an FceRI or FceRIa.

One embodiment of the present invention is a mutant IgE protein comprising an IgEH~ that has been modified in such a way as to cause the IgE protein to be constrained in the closed conformation. IgE proteins constrained in the closed conformation have IgEH~'s in which the N-terminal amino acid residues of the Ce3 domains are less than 23A apart; such mutant IgE proteins are unable to flex significantly enough to allow an inter-residue distance of 23~ or more. Suitable IgE proteins of the present invention include those in which the N-terminal amino acid residues of the IgEH~ Ce3 domains can achieve an inter-residue distance of from about 13A to less than 23A. As such, useful mutant IgE proteins of the present invention include those in which the N-terminal amino acid residues of the IgEH~ Ce3 domains can achieve an inter-residue distance of no greater than about 13A, no greater than about 14A, no greater than about 15A, no greater than about 16A, no greater than about 17A, no greater than about 18A, no greater than about 19A, no greater than about 20A, no greater than about 21A or no greater than about 22A or less than 23A. Such mutant IgE proteins can be isolated from natural sources or they can be produced by laboratory manipulation of unmodified IgE proteins, IgEH~'s andlor related nucleic acid molecules. Suitable methods to modify an IgE
protein are known to those skilled in the art and include, but are not limited to, chemical or enzymatic modification of the IgEH~'s, alteration of the IgEH~ protein sequences to produce a mutant protein giving the desired conformation, alteration of a nucleic acid molecule encoding IgEH~ s and combinations thereof; examples of such methods are described in more detail herein. A particularly useful mutant IgE protein is one that is constrained in the closed conformation and is unable to adopt the open conformation and as a result, is unable,to bind to a FceRI or FceRIa.
One embodiment of the present invention is a mutant IgE protein comprising an IgEH~ that comprises an amino acid sequence having at least 50% identity to SEQ ID
N0:11, wherein the amino acid sequence of the mutant IgEH~ has been modified to allow the IgEH~'s to form cross-linking covalent bonds thereby constraining movement of such IgEH~'s in an IgE protein. A suitable type of bond to form is a disulfide bond. Methods to determine percent identities and similarities are well known to those skilled in the art.
Examples of mutant IgE proteins include, but are nor limited to, those comprising an IgEH~ that comprises an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or at least about 100%
identical to SEQ ID N0:11, but wherein the amino acid residue in the IgEH~ corresponding to position 2, 3, 4, 5, 6, 7, 8, or 9 of SEQ ID N0:11 is a cysteine or a methionine.
In one embodiment, a mutant IgE protein of the present invention comprises an IgEIjo that comprises an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or at least about 100%
identical to an amino acid sequence selected from the group consisting of:
(a) SEQ ID N0:13, wherein the amino acid residue in said IgEH~ corresponding to position 2 of SEQ ID N0:13 is a cysteine or a methionine;
(b) SEQ ID N0:15, wherein the amino acid residue in said IgEH~ corresponding to position 3 of SEQ ID N0:15 is a cysteine or a methionine;
(c) SEQ ID N0:17, wherein the amino acid residue in said IgEH~ corresponding to position 4 of SEQ ID N0:17 is a cysteine or a methionine;
(d) SEQ ID N0:19, wherein the amino acid residue in said IgEH~ corresponding to position 5 of SEQ ID N0:19 is a cysteine or a methionine;
(e) SEQ ID N0:21, wherein the amino acid residue in said IgEH~ corresponding to position 6 of SEQ ID N0:21 is a cysteine or a methionine;
(f) SEQ ID N0:23, wherein the amino acid residue in said IgEH~ corresponding to position 7 of SEQ ID N0:23 is a cysteine or a methionine;
(g) SEQ ID N0:25, wherein the amino acid residue in said IgEH~ corresponding to position 8 of SEQ ID N0:25 is a cysteine or a methionine; and (h) SEQ ID N0:27, wherein the amino acid residue in said IgEH~ corresponding to position 9 of SEQ ID N0:27 is a cysteine or a methionine.
In a particularly useful embodiment, a mutant IgE protein comprises an IgEH~
that comprises an amino acid sequence selected from the group consisting of SEQ ID
N0:13, SEQ ID N0:15, SEQ ID N0:17, S,EQ ID N0:19, SEQ ID N0:21, SEQ ID N0:23, SEQ
ID N0:25 and SEQ ID N0:27.
The present invention also provides an isolated mutant IgEH~ modified in such a way as to cause an IgE protein comprising the mutant IgEH~ to have reduced spatial mobility in comparison to the spatial mobility of an IgE protein comprising an unmodified IgEH~. A suitable mutant IgEH~ is one which causes an IgE protein to be constrained in an open or closed conformation, with the closed conformation being preferred. Suitable mutant IgEH~'s of the present invention comprise an amino acid sequence having at least 50% identity to SEQ ID NO:11, but wherein the IgEH~
has been modified, allowing the formation of covalent bonds between two or more IgEHO's thereby constraining the movement of such IgEH~'s in an IgE protein. Preferred mutant IgEH~'s, while they no longer bind FceRI or FceRIa with the affinity of an IgEH~
comprising SEQ
ID NO:11, do retain other functions of IgEH~'s, for example the ability to elicit an immune response to an unmodified IgEH~ and the ability to bind to antibodies generated using an unmodified IgEH~. Any unmodified or mutant IgE protein or IgEH~ or related nucleic acid molecule can be subjected to modification to produce a mutant IgE
or a mutant IgEH~ or related nucleic acid molecule of the present invention.
Preferred proteins or nucleic acid molecules to modify are mammalian, with human, non-human IO primate, feline, canine, equine, murine, ovine, bovine or porcine protein or nucleic acid molecules being preferred. Particularly preferred are human, feline, canine or equine proteins or nucleic acid molecules with human proteins or nucleic acid molecules being more preferred. Methods of modifying IgEH~'s to allow the formation of inter-chain covalent bonds, such as, but not limited to disulfide bonds, are known to those skilled in the art and include, but are not limited to, chemical and/or enzymatic modification of the IgEH~'s, alteration of the IgEH~ protein sequence through the use of protein or recombinant technologies, and combinations thereof. A suitable type of bond to form is a disulfide bond. Any method of modification that causes an IgE protein comprising the modified IgEH~ to be constrained in the closed conformation may be used to produce IgEH~'s and IgE proteins of the present invention. A particularly useful embodiment is one that modifies the IgEH~ in such a way as to result in the N-terminal amino acids of the Ce3 domains in an IgE protein comprising the modified IgEH~ being no more than about 13A, no more than about 14A, no more than about 15A, no more than about 16A, no more than about 17A, no more than about 18 A,no more than about 19A , no more than about 20A , no more than about 21A, no more than about 22A apaxt, or less than apart.
One example of a useful method of modification is a chemical or enzymatic treatment. Suitable chemical or enzymatic treatments are well known to those skilled in the art and include, but are not limited to, for example, glycosylation reactions, myristilation reactions, biotinylation reactions, reduction reactions, oxidation reactions, protease reactions and the like. A suitable treatment is one which cross-links the IgEH~'s thereby constraining an IgE protein comprising the modified IgEH~ in the closed conformation.

In one embodiment, an IgEIjc is modified by altering the amino acid sequence.
A
mutant IgEHC may have one or more sequence differences compared to the unmodified IgEHC sequence and these sequence differences may arise naturally or they may be introduced through laboratory manipulation (e.g. substitutions, insertions, deletions) of an IgEHC protein or a nucleic acid molecule encoding such an IgEHC. Any alteration in the IgEHC amino acid sequence that results in an IgE protein that comprises the mutant IgEHc being constrained to the closed conformation are suitable. Such sequence alterations can be made at any location in the IgEHC that results in the IgE protein being constrained in the closed conformation. Particularly suitable positions at which to make modifications are positions in the Ce2/Ce3 linker region, the Ce3 domain and/or the Ce4 domain. For example, according to U.S. Patent Publication No. 20010039479-A1, Jardetzky et al., published on November 8, 2001, and U.S. Patent Publication No. 20030003502-A1, Jardetzky et al., published on January 2, 2003, the human IgEHC Ce3 domain spans amino acids 9 through 107 of SEQ ID N0:11, which correspond to amino acids 336 through 434 of full length human IgEHC , using the numbering system of Dorrington et al., 1978, Ir~zniuyzol Rev 41, 3-25, which is incorporated herein by reference in its entirety, while the Ce4 domain spans amino acids 114 through 220 of SEQ ID N0:11, which correspond to amino acids 441 through 547 of full length human IgEHC, using the numbering system of Dorrington et al., 1978, Immunol Rev 41, 3-25. As such, IgE Ce3/Ce4 extends from amino acids 9-220 of SEQ ID N0:11. A suitable embodiment is an IgEHC in which the amino acid sequence of the Ce2/Ce3 linker region.is altered by the addition, substitution or deletion of amino acids. For example, according to U.S. Patent Publication No.
20010039479-A1, Jardetzky et al., published on November 8, 2001, and U.S.
Patent Publication No. 20030003502-Al, Jardetzky et al., published on January 2, 2003, the IgEHC Ce2/Ce3 linker region spans amino acids 1-8 of SEQ ID N0:11, which correspond to amino acids 328 through 335 of the full length human IgEHC, using the numbering system of Dorrington et al. Particularly preferred positions at which to substitute or insert a cross-linking amino acid include, but are not limited to, amino acid position 2, 3, 4, 5, 6, 7, 8 or 9 of SEQ ID N0:11. While these position numbers refer to amino acid positions in SEQ ID N0:11, it should be noted that these amino acids are commonly referred to as, and correspond to, amino acids A329, D330, 5331, N332, P333, 8334, 6335 and of full-length IgEHC, using the numbering system of Dorrington et al., 1978, Imn2urcol Rev 41, 3-25. The same mutations could be made at the corresponding amino acids in the full-length IgEH~ or within corresponding positions in IgE Fc-region fragments either alone or contained within other proteins.
A particularly useful type of modification is the introduction of a cysteine residue or a methionine residue into an IgEHC. Such an introduction can result from an insertion of an additional amino acid residue (i.e. cysteine or methionine) into the sequence or from the conversion of an existing amino acid residue into a cysteine or a methionine.
Methods of producing such mutants are known to those skilled in the art. One such method is through the manipulation of an IgEH~ nucleic acid molecule (e.g. by nucleotide insertions, deletions andlor substitutions) to produce a nucleic acid molecule encoding a desired mutant IgEH~. Nucleic acid molecules can be modified using a variety of techniques known to one skilled in the art such as, for example, site-directed mutagenesis, chemical treatment, restriction enzyme cleavage, ligation of nucleic acid fragments, polymerase chain reaction (PCR) amplification, PCR mutagenesis, synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" a mixture of nucleic acid molecules, in-vitro or directed evolution and combinations thereof. The use of such techniques are known to those skilled in the art; see for example, Sambrook, et al., 1989, Molecular- Cloning: A Laboratory Manual, Cold Spring Harbor Labs Press which is incorporated herein by reference in its entirety.
In one embodiment a mutant IgEH~ comprises an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%
or at least about 100% identical to SEQ ID NO:11, but wherein the amino acid residue in said IgEH~ corresponding to position 2, 3, 4, 5, 6, 7, 8, or 9 of SEQ ID N0:11 is a cysteine or a methionine. In one embodiment, an IgEH~ of the present invention comprises an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or at least about 100% identical to an amino acid sequence selected from the group consisting of:
(a) SEQ ID N0:13, wherein the amino acid residue in said IgEH~ corresponding to position 2 of SEQ ID N0:13 is a cysteine or a methionine;
(b) SEQ ID N0:15, wherein the amino acid residue in said IgEH~ corresponding to position 3 of SEQ ID N0:15 is a cysteine or a methionine;
(c) SEQ ID N0:17, wherein the amino acid residue in said IgEH~ corresponding to position 4 of SEQ ID N0:17 is a cysteine or a methionine;

(d) SEQ ID N0:19, wherein the amino acid residue in said IgEHC corresponding to position 5 of SEQ ff~ N0:19 is a cysteine or a methionine;
(e) SEQ ID N0:21, wherein the amino acid residue in said IgEHC corresponding to position 6 of SEQ ID NO:21 is a cysteine or a methionine;
(f) SEQ ID N0:23, wherein the amino acid residue in said IgEHC corresponding to position 7 of SEQ ID N0:23 is a cysteine or a methionine;
(g) SEQ ID N0:25, wherein the amino acid residue in said IgEHC corresponding to position 8 of SEQ ID N0:25 is a cysteine or a methionine; and (h) SEQ ID N0:27, wherein the amino acid residue in said IgEHC corresponding to position 9 of SEQ ID N0:27 is a cysteine or a methionine. Particularly useful IgEHC's of the present invention are IgEHC's comprising an amino acid sequence selected from the group consisting of SEQ ID N0:13, SEQ ID N0:15, SEQ ID N0:17, SEQ ID N0:19, SEQ ID N0:21, SEQ ID N0:23, SEQ ID N0:25, SEQ ID N0:27, SEQ ID NO:29, SEQ
ID N0:31, SEQ ID N0:33, SEQ ID N0:35, SEQ ID N0:37, SEQ ID N0:39, SEQ ID
N0:41, SEQ ID N0:43, SEQ ID N0:45, SEQ ID N0:47, SEQ ID N0:49.
One embodiment of the present invention is a method to produce an IgE protein that is constrained in the closed conformation, said method comprising: (a) altering the nucleic acid sequence of a nucleic acid molecule encoding an unmodified IgEHC;
and (b) using the modified IgEHC nucleic acid molecule to produce a mutant IgE
protein constrained in the closed conformation. In a preferred embodiment, the nucleic acid sequence is modified so that one or more cysteine residues are introduced into the IgEHc protein. In a more preferred embodiment, the nucleic acid sequence is altered to encode a protein which has cysteine residues in a position corresponding to position 2, 3, 4, 5, 6, 7, 8 and/or 9 of SEQ ID NO:11.
The present invention also provides isolated mutant IgEHC proteins lacking one or more N-linked glycosylation sites. The human IgEHC is known to have at least three potential N-linked glycosylation sites. For example,. the human IgEHC can potentially be glycosylated at amino acids 44, 56 and/or 67 of SEQ ID NO:11, which correspond to amino acids 371, 373 and 394 of the full-length IgE using the numbering system of Dorrington et al., 1978, Ifnmunol. Rev 41, 3-25. A useful embodiment of the present invention is an isolated mutant IgEHC in which the sequence of one or more of the potential N-linked glycosylation sites have been modified such that the cellular glycosylation mechanism does not attach a carbohydrate moiety at that site.
Suitable modifications include amino acid substitutions, deletions and additions.
Methods of malting such modifications are known to those skilled in the art and include, for example, altering a nucleic acid sequence encoding an IgEH~. A useful modification to make is one that modifies one or more amino acids from positions 44 through 46 of SEQ ID
N0:11 and/or positions 56 through 58 of SEQ ID N0:11. A particularly useful embodiment is an isolated mutant IgEH~ in which the asparagine at position 44 of SEQ ID
N0:11 and/or the asparagine at position 56 of SEQ ID N0:11 has been replaced by an amino acid other than an asparagine. Suitable embodiments include isolated mutant IgEH~'s comprising an amino acid sequence at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 100% identical to SEQ ID NO:1 l, but wherein the amino acid at position 44 and/or 56 of SEQ ID NO:11 is not an asparagine. A
particularly suitable embodiment is an isolated mutant IgEH~ comprising the amino acid sequence of SEQ ID N0:8. Also contemplated are mutant IgE proteins comprising a mutant IgEH~ in which one or more glycosylation sites have been altered to prevent glycosylation at the modified site.
The present invention also provides 3-dimensional models of mutant IgE
proteins comprising a mutant IgEH~ in which one or more glycosylation sites have been altered to prevent glycosylation at the modified site. Such models can describe a mutant IgE
protein in the open or closed conformation and can be used to design or find compounds that inhibit the binding of IgE to an FceRI or FceRIa.
One embodiment of the present invention is a nucleic acid molecule that encodes a protein of the present invention. Useful nucleic acid molecules include those that encode an IgEH~ comprising an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or at least about 100%
identical to SEQ ID NO:11, but wherein the amino acid residue in said IgEHc corresponding to position 2, 3, 4, 5, 6, 7, 8, or 9 of SEQ ID N0:11 is a cysteine or a methionine. Particularlyuseful nucleic acid molecules include those that encode a mutant IgEH~ comprising an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or at least about 100%
identical to an amino acid sequence selected from the group consisting of:
(a) SEQ ID N0:13, wherein the amino acid residue in said IgEH~ corresponding to position 2 of SEQ ID N0:13 is a cysteine or a methionine;

(b) SEQ ID N0:15, wherein the amino acid residue in said IgEH~ corresponding to position 3 of SEQ ID N0:15 is a cysteine or a methionine;
(c) SEQ ID N0:17, wherein the amino acid residue in said IgEH~ corresponding to position 4 of SEQ ID N0:17 is a cysteine or a methionine;
(d) SEQ ID N0:19, wherein the amino acid residue in said IgEH~ corresponding to position 5 of SEQ ID N0:19 is a cysteine or a methionine;
(e) SEQ ID N0:21, wherein the amino acid residue in said IgEH~ corresponding to position 6 of SEQ ID N0:21 is a cysteine or a methionine;
(f) SEQ ID NO:23, wherein the amino acid residue in said IgEH~ corresponding to position 7 of SEQ ID N0:23 is a cysteine or a methionine;
(g) SEQ ID N0:25, wherein the amino acid residue in said IgEH~ corresponding to position 8 of SEQ ID N0:25 is a cysteine or a methionine; and (h) SEQ ID N0:27, wherein the amino acid residue in said IgEH~ corresponding to position 9 of SEQ ID N0:27 is a cysteine or a methionine.
Preferred nucleic acid molecules are those that encode an IgEH~ comprising an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98% or at least about 100% identical to an amino acid sequence selected from the group consisting of SEQ ID N0:2, SEQ ID N0:8, SEQ ID N0:11, SEQ
ID N0:13, SEQ ID N0:15, SEQ ID N0:17, SEQ ID N0:19, SEQ ID N0:21, SEQ ID
N0:23, SEQ ID NO:25 and SEQ ID N0:27.
Nucleic acid molecules useful in the present invention can be produced by, for example, recombinant nucleic acid technology or by chemical synthesis. A
nucleic aid molecule of the present invention can be DNA, RNA, or a derivative of DNA and RNA.
Nucleic acid molecules of the present invention include natural forms, including allelic variants, nucleic acid molecules optimized for expression in a particular host and other nucleic acid molecules modified by nucleotide insertions, deletions, substitutions and/or inversions. A useful nucleic acid molecule of the present invention is a nucleic acid molecule comprising a nucleic acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or at least about 100% identical in sequence to SEQ ID N0:1, SEQ ID N0:3, SEQ ID NO:4, SEQ
ID N0:5, SEQ ID N0:6, SEQ ID N0:7, SEQ ID N0:9, SEQ ID N0:10, SEQ ID N0:12, SEQ ID N0:14, SEQ ID N0:16, SEQ ID N0:18, SEQ ID N0:20, SEQ ID N0:22, SEQ
ID NO:24 or SEQ ID N0:26, wherein the nucleic acid sequence encodes a protein that elicits an immune response to an IgEH~ protein that comprises the amino acid sequence of SEQ ID N0:11.
One embodiment of the present invention is a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:
(a) a nucleic acid sequence at least about 90%, at least about 95%, at least about 98%, at least about 100% identical to SEQ ID N0:10, wherein the codon in said nucleic acid sequence corresponding to the codon at position 2 of SEQ ID NO:10 encodes a cysteine or a methionine;
(b) a nucleic acid sequence at least about 90%, at least about 95%, at least about 98%, at least about 100% identical to SEQ ID NO:10, wherein the codon in said nucleic acid sequence corresponding to the codon at position 3 of SEQ ID NO:10 encodes a cysteine or a methionine;
(c) a nucleic acid sequence at least about 90%, at least about 95%, at least about 98%, at least about 100% identical to SEQ ID NO:10, wherein the codon in said nucleic acid sequence corresponding to the codon at position 4 of SEQ ID NO:10 encodes a cysteine or a methionine;
(d) a nucleic acid sequence at least about 90%, at least about 95%, at least about 98%, at least about 100% identical to SEQ ID N0:10, wherein the codon in said nucleic acid sequence corresponding to the codon at position 5 of SEQ ID N0:10 encodes a cysteine or a methionine;
(e) a nucleic acid sequence at least about 90%, at least about 95%, at least about 98%, at least about 100% identical to SEQ ID NO:10, wherein the codon in said nucleic acid sequence corresponding to the codon at position 6 of SEQ ID NO:10 encodes a cysteine or a methionine;
(f) a nucleic acid sequence at least about 90%, at least about 95%, at least about 98%, at least about 100% identical to SEQ ID NO:10, wherein the codon in said nucleic acid sequence corresponding to the codon at position 7 of SEQ ID NO:10 encodes a cysteine or a methionine;
(g) a nucleic acid sequence at least about 90%, at least about 95%, at least about 98%, at least about 100% identical to SEQ ID NO:10, wherein the codon in said nucleic acid sequence corresponding to the codon at position 8 of SEQ ID NO:10 encodes a cysteine or a methionine; and (h) a nucleic acid sequence at least about 90%, at least about 95%, at least about 98%, at least about 100% identical to SEQ ID N0:10, wherein the codon in said nucleic acid sequence corresponding to the codon at position 9 of SEQ ID N0:10 encodes a cysteine or a methionine.
It should be noted that it is well known by those skilled in the art a codon consists of 3 nucleotides and that references to a codon position in a SEQ ID NO. refers to the 3 nucleotides making that make up that codon. For example, reference to the codon at position 2 of SEQ ID NO:10 refers to nucleotides 4-6 of SEQ ID N0:10.
A preferred nucleic acid molecule is one having the above characteristics and which encodes a protein having functions including, but not limited to antigen binding, eliciting an immune response to an IgE protein comprising an IgEHC that comprises an amino acid sequence of SEQ ID NO:11 and binding an antibody generated to an IgE protein comprising an IgEH~ that comprises an amino acid sequence of SEQ ID NO:11.
A suitable nucleic acid molecule of the present invention is a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO:1, SEQ ID
N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, SEQ ID N0:7, SEQ ID N0:9, SEQ
ID N0:10, SEQ ID N0:12, SEQ ID NO:14, SEQ ID N0:16, SEQ ID N0:18, SEQ ID
N0:20, SEQ ID N0:22, SEQ ff~ N0:24, SEQ ID N0:26, SEQ ID N0:28, SEQ ID
N0:30, SEQ ID N0:32, SEQ ID N0:34, SEQ ID N0:36, SEQ ID N0:38, SEQ ID
N0:40, SEQ ID N0:42, SEQ ID N0:44, SEQ ID N0:46, SEQ ID N0:48.
One embodiment of the present invention is a recombinant molecule that comprises a nucleic acid molecule operatively linked to a transcriptional control sequence. The phrase operatively linked refers to joining of a nucleic acid molecule to a transcription control sequence in a manner such that the molecule is able to be expressed when transformed into a host organism. A suitable host organism is any organism capable of directing expression from a nucleic acid molecule of the present invention. As used herein, an expression vector is a DNA or RNA vector, typically either a plasmid or viral genome, that is capable of transforming a cell and of effecting expression of a specified nucleic acid molecule. A preferred recombinant molecule of the present invention contains regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that axe compatible with the recombinant microorganism and that control the expression of nucleic acid molecules of the present invention. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription.
Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences.
Suitable transcription control sequences include any transcription control sequence that can function in at least one of the recombinant microorganisms of the present invention.
A variety of such transcription control sequences are known to those skilled in the art;
examples included, but are not limited to, tac, lac, trp, tf-c, oxy-pro, omp/Ipp, rrnB, bacteriophage lambda (such as lambda pL, also referred to herein as lambda PL) and lambda pR (also referred to herein as lambda PR) and fusions that include such promoters), bacteriophage T7, T7lae, bacteriophage T3, bacteriophage SP6, SPO1, alpha-mating factor, alcohol oxidase (AOX), antibiotic resistance gene, and other sequences capable of controlling gene expression in E. coli , methyltrophic yeast microorganisms, insect cells or other cells useful for expressing proteins; it is to be noted that this list is not intended to be limiting as many additional transcriptional control sequences are known.
A preferred recombinant molecule includes a nucleic acid molecule that encodes an IgEHc of the present invention, operatively linked to an insect cell promoter.
Another embodunent of the present invention includes a recombinant vector, which includes at least one isolated nucleic acid molecule of the present invention, inserted into any vector capable of delivering the nucleic acid molecule into a host cell.
Such a recombinant vector contains heterologous nucleic acid sequences, that is nucleic acid sequences that are not naturally found adjacent to nucleic acid molecules of the present invention and that preferably axe derived from a species other than the species from which the nucleic acid molecules) axe derived. The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a virus or a plasmid.
Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulation of IgE nucleic acid molecules of the present invention.
One embodiment of the present invention is a recombinant cell, which is a host cell transformed with a nucleic acid molecule of the present invention. A
preferred recombinant molecule comprises a recombinant molecule of the present invention.
Recombinant DNA technologies can be used to improve expression of transformed nucleic acid molecules by manipulating, for example, the number of copies of the nucleic acid molecules within a host cell, the efficiency with which those nucleic acid molecules are transcribed, the efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications.
Recombinant techniques useful for increasing the expression of nucleic acid molecules of the present invention include, but are not limited to, operatively linking nucleic acid molecules to high-copy number plasmids, integration of the nucleic acid molecules into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals (e.g., ribosome binding sites, Shine-Dalgarno sequences), modification of nucleic acid molecules of the present invention to correspond to the codon usage of the host cell, deletion of sequences that destabilize transcripts, and use of control signals that temporally separate recombinant cell growth from recombinant enzyme production during fermentation. The activity of an expressed recombinant protein of the present invention may be improved by fragmenting, modifying, or derivatizing nucleic acid molecules encoding such a protein.
One embodiment of an IgEH~ of the present invention is a fusion protein.
Suitable fusion segments for use with the present invention include, but are not limited to, segments that can: link two or more IgEH~ proteins of the present invention to form multimers; enhance a protein's stability; facilitate the purification of an IgEHC protein;
and/or to affect the immune response to an IgE or IgEHO protein. A suitable fusion segment can be a domain of any size that has the desired function (e.g., imparts increased stability, imparts increased immunogenicity to a protein, and/or simplifies purification of a protein). Fusion segments can be joined to amino and/or carboxyl termini of an IgEHc of the present invention and can be susceptible to cleavage in order to enable straight-forward recovery of such protein. Fusion proteins are preferably produced by culturing a recombinant cell transformed with a fusion nucleic acid molecule that encodes a protein including the fusion segment attached to either the carboxyl and/or amino terminal end of an IgEHC protein. Preferred fusion segments include a metal binding domain (e.g., a poly-histidine segment); an immunoglobulin binding domain (e.g., Protein A; Protein G; T cell; B cell; Fc receptor or complement protein antibody-binding domains); a sugar binding domain (e.g., a maltose binding domain); and/or a "tag"
domain (e.g., at least a portion of (3-galactosidase, a strep tag peptide, a T7 tag peptide, a FIagTM peptide, or other domains that can be purified using compounds that bind to the domain, such as monoclonal antibodies). More preferred fusion segments include metal binding domains, such as a poly-histidine segment; a maltose binding domain; a strep tag peptide, such as that available from Biometra in Tampa, FL; and an S10 peptide.
Effective culturing conditions to produce a mutant IgEH~ or a mutant IgE
protein of the present invention include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production. An effective medium refers to any medium in which a cell is cultured to produce an a mutant IgEHC or a mutant IgE protein of the present invention. Such a medium typically comprises an aqueous medium having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins.
Recombinant cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for yeast, E. eoli, insect cells or other cells suitable for culture. Determining such culturing conditions are within the expertise of one of ordinary skill in the art.
Depending on the vector and host system used for production, resultant proteins of the present invention may either remain within the recombinant cell; be secreted into the culturing, or fermentation, medium; or be secreted into a space between two cellular membranes. In a preferred embodiment, the protein is in the medium and, hence, can be easily separated from the cell.
Proteins of the present invention can be purified using a variety of purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A
chromatography, chromatofocusing and differential solubilization. Proteins of the present invention are preferably retrieved in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the protein as a diagnostic, therapeutic or prophylactic, or as a screening tool.
The ability of IgEHC or IgE proteins of the present invention as well as of unmodified IgEH~ or IgE proteins to selectively bind to FceRI or FceRIa protein can be assayed by methods known in the art, such as, but not limited to, those disclosed herein and in PCT Publication No. WO 00/26246, Jardetzky et al., published May 11, 2000; U.S.
Patent Publication No. 20030003502-A1, Jardetzky et al., published January 2, 2003;
PCT Publication No. WO 01/69253 A3, Jardetzky et al., published September 20, 2001;

U.S. Patent Publication No. 20010039479, Jardetzky et al., published November 8, 2001;
and PCT Publication No. WO 01/68861 A3, Jardetzky et al., published September 20, 2001. As used herein, the term, selectively binds to FceRI or to FceRIa protein refers to the ability of a protein to preferentially bind to FceRI or FceRIa protein, without being able to substantially bind to other FcR proteins. Preferably, an FceRI or FceRIa binds to an IgE protein with an affinity (IAA) of at least about 10s liters/mole (M-1), more preferably of at least about 109 M-1, and even more preferably of at least about 101° M-1.
Methods to compare binding activity of the mutant proteins of the present invention with the binding activity of unmodified proteins are also known in the art and include, but are not limited to, those methods disclosed herein and in PCT Publication No. WO
00/26246, Jardetzky et al., published May 11, 2000; U.S. Patent Publication No.
20030003502-Al, Jardetzky et al., published January 2, 2003; PCT Publication No. WO 01/69253 A3, Jardetzky et al., published September 20, 2001; U.S. Patent Publication No.
20010039479, Jardetzky et al., published November 8, 2001; and PCT Publication No.
WO 01/68861 A3, Jardetzky et al., published September 20, 2001.
The present invention also includes a method to identify a compound that binds to an IgE protein, thereby placing, restraining, maintaining or stabilizing that IgE protein in a closed form (i.e., such compound binds to an IgE protein either in or resulting in a closed conformation). Preferably such a compound inhibits an IgE protein from binding to Fc~RI. It is to be appreciated that methods to identify such a compound can utilize unmodified or mutant IgEH~ or IgE proteins of the present invention. As such, although the methods discussed below may cite the use of a mutant IgE protein, it is to be appreciated that mutant IgEH~ proteins of the present invention can also be used.
One embodiment is a method to identify a compound that binds the closed form of an IgE protein, said method comprising: (a) contacting a mutant IgE protein constrained in the closed form with a candidate compound; and (b) determining if such candidate compound binds to the IgE closed form mutant. In a preferred embodiment, such candidate compound, assuming it bound to the closed form of an IgE protein, is then contacted with IgE and an FcsRI or FcsRIa protein to determine whether such candidate compound inhibits binding between IgE and such FcsRI or FcaRIa protein. In another preferred embodiment, such candidate compound, assuming it bound to a closed form of an IgE protein, is also contacted with an IgE protein in the open conformation to determine if the candidate compound binds to IgE in the open conformation.
Another embodiment is a method to identify a compound that inhibits the binding of IgE
to FcsRI
by a method comprising: (a) contacting a mutant IgE protein constrained in the closed form with a candidate compound in the presence of a FcsRI or FcsRIa protein;
and (b) determining if such candidate compound inhibits binding of the IgE protein to the FcsRI
or FcsRIa protein.
A preferred compound is one that selectively binds an IgE protein in the closed conformation. As used herein, the term, selectively binds to the closed conformation of an IgE protein, refers to the ability of a compound to preferentially bind to the closed conformation of an IgE protein, without being able to substantially bind to other proteins or molecules, including an IgE protein in the open conformation. A compound that is capable of selectively binding to an IgE protein is also referred to herein as an IgE-binding compound. A particularly preferred compound is a compound that binds to an IgE protein in the closed conformation, but not in the open conformation (except to cause such IgE to adopt a closed conformation) and that inhibits the binding of an IgE protein to FcsRI or FcERIa.
Suitable binding assays are known to those skilled in the art and are conducted under conditions suitable to form a binding complex; such conditions, e.g., appropriate concentrations, buffers, temperatures, reaction times, as well as methods to optimize such conditions are known to those skilled in the art. See, for example Wingfiled, et a1.,1996, Current Protocols in Protein Science, Volume 1, John Wiley and Sons Publisher, which is incorporated herein in its entirety by reference, Sambrook et al., ibid., PCT
Publication No. WO 00/26246, Jardetzky et al., published May 11, 2000; U.S. Patent Publication No.
20030003502-A1, Jardetzky et al., published January 2, 2003; PCT Publication No. WO
01/69253 A3, Jardetzky et al., published September 20, 2001; U.S. Patent Publication No.
20010039479, Jardetzky et al., published November 8, 2001; and PCT Publication No.
WO 01/68861 A3, Jardetzky et al., published September 20, 2001, and Example 1.
Examples of assays useful for detecting binding of a compound to an IgE
protein include, but are not limited to, an enzyme-linked immunoassay, a radioimmunoassay, a fluorescence immunoassay, a chemiluminescent assay, a lateral flow assay, an agglutination assay, a particulate-based assay, e.g., using particulates such as, but not limited to, magnetic particles or plastic polymers, such as latex or polystyrene beads, an immunoprecipitation assay, a BioCoreTM assay, e.g., using colloidal gold, and an immunoblotting assay, e.g., a western blot. Such assays are well known to those skilled in the art. Assays can be used to give qualitative or quantitative results depending on how they are used. Some assays, such as agglutination, particulate separation, and immunoprecipitation, can be observed visually, e.g., either by eye or by a machine, such as a densitometer or spectrophotometer, without the need for a detectable marker. In other assays, conjugation, i.e., attachment, of a detectable marker to one of the binding components of the assay aids in detecting complex formation. Examples of detectable markers include, but are not limited to, a radioactive label, an enzyme, a fluorescent label, a chemiluminescent label, a chromophoric label or a ligand. A ligand refers to a molecule that binds selectively to another molecule. Preferred detectable markers include, but are not limited to, fluorescein, a radioisotope, a phosphatase, e.g., alkaline phosphatase, biotin, avidin, a peroxidase, e.g., horseradish peroxidase, and biotin-related compounds or avidin-related compounds, e.g., streptavidin or ImmunoPureO NeutrAvidin available from Pierce, Rockford, IL. Such methods can be used to test one or more compounds at a time. Preferred methods test more than one compound at the same time and can include screening methods to analyze many candidate compounds simultaneously. It is within the ability of one skilled in the art to optimize such assays to determine which compounds bind an IgE protein in the closed conformation, which compounds bind an IgE
protein in the open conformation, which compounds inhibit an IgE protein from binding to its receptor, which compounds do not bind an IgE protein in the closed conformation, and which compounds do not bind an IgE protein in the open conformation.
Suitable compounds that bind an IgE protein in the closed conformation can be naturally produced compounds or synthetically produced compounds and include proteins, carbohydrates, organic molecules, substrate analogs, and other large or small molecules. Such compounds may be identified, for example, by screening chemical libraries or phage display libraries and the like.
In one embodiment, a mixture of candidate compounds is applied to a column to which IgE protein in the open conformation has been immobilized. Compounds which flow through the column (those that do not bind IgE in the open conformation) are collected and applied to a second column to which IgE in the closed conformation has been immobilized. Compounds that do not bind this form of the IgE protein will flow through the column. Compounds which do bind IgE in the closed conformation are then eluted from the column for further analysis.

The present invention also includes a therapeutic composition comprising at least one IgE-binding compound of the present invention, a protein of the present invention or some combination thereof. A preferred compound to include in a therapeutic composition is one which binds the closed form of IgE and/or when bound to IgE
restrains the IgE from existing in an open conformation, thereby inhibiting the IgE from binding to a FcsRI. A particularly preferred compound to include in a therapeutic composition is one which inhibits binding of IgE to a FcsRI. Therapeutic compositions of the present invention can be formulated in an excipient that the animal to be treated can tolerate. Examples of such excipients include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions.
Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. Other useful formulations include suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran.
Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include thimerosal, or o-cresol, formalin and benzyl alcohol. Standard formulations can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a non-liquid formulation, the excipient can comprise dextrose, human serum albumin, preservatives, etc., to which sterile water or saline can be added prior to administration.
hi one embodiment of the present invention, a therapeutic composition can include a carrier. Carriers include compounds that increase the half-life of a therapeutic composition in the treated animal. Suitable carriers include, but are not limited to, polymeric controlled release vehicles, biodegradable implants, liposomes, bacteria, viruses, other cells, oils, esters, and glycols.
One embodiment of the present invention is a controlled release formulation that is capable of slowly releasing a composition of the present invention into an animal. As used herein, a controlled release formulation comprises a composition of the present invention in a controlled release vehicle. Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other controlled release formulations of the present invention include liquids that, upon administration to an animal, form a solid or a gel ifa situ. Preferred controlled release formulations are biodegradable, i.e., bioerodible.
In one embodiment, a therapeutic composition of the present invention can be used to protect an animal from a disease mediated by IgE by administering such composition to such animal in order to prevent undesirable effects of IgE. An example of an IgE-mediated disease is an allergy. In one embodiment, the therapeutic composition of the present invention is administered to reduce the activity and or amount of IgE in an animal. Such administration can include, but is not limited to, oral, intravenous, intramuscular, intra ocular, mucosal, intranasal, subcutaneous, or transdennal application.
A preferred route of administration is subcutaneous. In order to protect an animal from a disease mediated by IgE, a therapeutic composition of the present invention is administered to the animal in an effective manner such that the composition is capable of protecting that animal from a disease mediated by IgE. Therapeutic compositions of the present invention can be administered to animals prior to disease in order to prevent disease and/or can be administered to animals after disease occurs. The exact dose, administration regimen, and administration route of therapeutic compositions of the present invention can be determined by one skilled in the art. Additional teachings are provided, for example, in PCT Publication No. WO 00/26246, Jardetzky et al., published May 11, 2000; U.S. Patent Publication No. 20030003502-A1, Jardetzky et al., published January 2, 2003; PCT Publication No. WO 01/69253 A3, Jardetzky et al., published September 20, 2001; U.S. Patent Publication No. 20010039479, Jardetzky et al., published November 8, 2001; and PCT Publication No. WO 01/68861 A3, Jardetzky et al., published September 20, 2001.
One embodiment of the present invention is a kit comprising a mutant IgEH~ or IgE protein of the present invention. Such a kit is used to identify a compound that binds to IgE protein, preferably IgE protein in the closed conformation or that when such compound binds to IgE, prevents or restrains it from maintaining or achieving an open conformation. Such a kit may also comprise tubes, bottles, reagents, syringes, literature, packaging and the like.
The following example is provided for the purpose of illustration and is not intended to limit the scope of the present invention. The following example includes a number of recombinant DNA and protein chemistry techniques known to those skilled in the art; see for example Sambrook et al., ibid.
Example 1 This Example describes the construction and binding abilities of several cysteine mutants of IgEHC proteins or IgEHC's A. Construction of IgEH~ cysteine mutants:
Several mutant IgEH~ proteins were created by substituting a cysteine into an unmodified IgEH~ protein having SEQ ID N0:11 thereby enabling the potential formation of interchain disulfide bonds. The mutant proteins were created using polymerise chain reaction (PCR) mutagenesis as follows:
Using an unmodified (unmod) IgEH~ nucleic acid molecule having SEQ ID NO:10 as a template, mutant IgEH~ nucleic acid molecules were amplified by PCR, under standard conditions, using a 5' primer that introduced mutations creating a cysteine residue at various position. The 5' primers are as follows:

C328A 5'T AGG GCG GAT CCC GCT GCA GAT TCG AAC CCG AGA GGG GTG AGC G 3' (SEQ ID N0:28) Arg Ala Asp Pro Ala Ala Asp Ser Asn Pro Arg Gly Val Ser (SEQ ID N0:29) C328S 5°T AGG GCG GAT CCC TCT GCA GAT TCG AAC CCG AGA GGG GTG AGC
G 3' (SEQ ID N0:30) Arg Ala Asp Pro Ser Ala Asp Ser Asn Pro Arg Gly Val Ser (SEQ ID N0:31) C328 5'T AGG GCG GAT CCC TGT GCG GAT TCG AAC CCG AGA GGG GTG AG 3' (SEQ ID N0:32) Arg Ala Asp Pro Cys Ala Asp Ser Asn Pro Arg G1y Val (SEQ ID N0:33) C329 5'T AGG GCG GAT CCC gcg tgt GAT TCG AAC CCG AGA GGG GTG AG 3' (SEQ ID N0:34) Arg Ala Asp Pro Ala Cys Asp Ser Asn Pro Arg Gly Val (SEQ ID N0:35) C330 5'T AGG GCG GAT CCC gcg GCG tgt TCG AAC CCG AGA GGG GTG AG 3' (SEQ ID N0:36) Arg Ala Asp Pro Ala Ala Cys Ser Asn Pro Arg Gly Val (SEQ ID N0:37) C331 5'T AGG GCG GAT CCC gcg GCG GAT tgt AAC CCG AGA GGG GTG AG 3' (SEQ ID N0:38) Arg Ala Asp Pro Ala A1a Asp Cys Asn Pro Arg Gly Val (SEQ ID N0:28) C332 5'T AGG GCG GAT CCC geg GCG GAT TCG tgt CCG AGA GGG GTG AG 3' (SEQ ID N0:39) Arg Ala Asp Pro Ala Ala Asp Ser Cys Pro Arg Gly Val (SEQ ID N0:40) C333 5'T AGG GCG GAT CCC gcg GCG GAT TCG AAC tgt AGA GGG GTG AG 3' (SEQ IDN0:41) Arg Ala AspProAla AlaAspSer CysArg G1yVal Asn S (SEQ IDNO:42) C334 5'T AGG GATCCCgcg GCGGATTCG CCGtgt GGGGTG AG
GCG AAC 3' (SEQ IDN0:43) Arg Ala AspProAla AlaAspSer ProCys GlyVal Asn 10(SEQ IDN0:44) C335 5'T AGG GATCCCgcg GCGGATTCG CCGAGA tgtGTG AG
GCG AAC 3' (SEQ IDNO:45) Arg Ala AspProAla A1aAspSer ProArg CysVal Asn 15(SEQ IDN0:46) C336 5'T GATCCCgcg GCGGATTCG CCGAGA GGGtgt AG
AGG AAC 3' GCG

(SEQ IDN0:47) Arg Ala AspProAla AlaAspSer ProArg GlyCys Asn 20(SEQ IDN0:48) Each of the mutant IgEH~ nucleic acid molecules was ligated into the expression vector pAcGP67A (Catalog Number 221220P, Becton Dickinson Pharmingen, Franklin Lakes, N.J.). The encoded sequence of the N-terminus of the mature (signal sequence cleaved) 25 protein is ADPCAD with C corresponding to C328 of the mature IgE using the numbering according to Dorrington and Bennich, 1978, Ini~nunol Rev 41, 3-25.
The plasmids were transformed into insect (HI-5) insect cells using standard protocols, expressed and the resulting proteins analyzed using western blot analysis.
B. Western-blot analysis of unmodified and mutant IgEH~'s 30 Following expression in insect cells, the IgEH~ proteins were analyzed by western-blot analysis. Samples of infected cell supernatants were added to PAGe sample buffer either with or without reducing agent (e.g. 5 mM DTT). The samples were then boiled and separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGe). Following separation, the proteins were transferred to Immobilon membranes and the,proteins 35 visualized using an alkaline-phosphatase conjugated, goat anti-human polyclonal anti-IgE
antibody (Catalog 075-1004, Kirkegaard & Perry Labs, Gaithersburg, MD) using standard western blotting protocol. The results of this analysis are shown in Figure 3.
C. Ability of mutmt IgEH~ proteins to bind FceRIa The ability of the unmodified and mutant IgEH~ proteins to bind the FceRIa 40 protein was compared using an ELISA assay as follows:
The wells of a microtiter plate were coated (50 ng/well) with human FceRIa (produced as described in U.S. Patent Publication No. US-2001-0039479-A1) in PBS and the plate incubated overnight at 4°C. The plate was washed 3X with WASH
buffer (0.5%

Tween-20 in 10 rnM Tris, pH 7.5, 150 mM NaCL) and blocked for one hour at room temperature (RT) using BLOCK buffer (5 °Io dried milk. in 10 mM Tris, pH 7.5, 150 mM
NaCL). The plate was again washed 3X with WASH buffer and 100 ~,l of IgEHO
(either unmodified IgEH~ or mutant IgEH~ diluted from 0.5 to 0.065 in BLOCK buffer) was added to various wells of the plate. To half of the samples was added 5 mM
DTT. The plate was then incubated for one hour at RT, washed 3X with WASH buffer, and 100 ~,1 of alkaline-phosphatase conjugated, goat anti-human polyclonal anti-IgE
antibody (Catalog 075-1004, Kirlcegaard & Perry Labs, Gaithersburg, MD)(use a 1:1000 dilution of stock solution) was added to each well. The plate was incubated at RT for one hour, washed 3X with WASH buffer, rinsed three times with water, and 50 ~.1 of p-nitrophenyl phosphate (PNPP) was added to each well. The plate was incubated for 30-60 minutes at RT and the reaction was stopped by the addition of I O ~,l of 0.5M EDTA. The plate was read at 450 nM using an ELISA plate reader. The results are shown below in Table 1.
Table 1.

(unmod) 5 mM DTT 5 mM 5 mM 5 mM
DTT DTT DTT

Dilution+ - + - + - + -0.5 0.224 0.257 0.14 0.2570.159 0.161 0.125 0.059 0.25 0.19 0.265 0.01550.1920.13 0.13 0.102 0.038 0.125 0.106 0.243 0 0.0650.039 0.075 0.08950.013 0.065 0.01150.195 -0.0030.0220.001 0.062 0.066 0.038 5 mM 5 mM 5 mM 5 mM
DTT DTT DTT DTT

Dilution+ - + - + - + -0.5 0.11 0.032 0.16250.1090.0185-0.0040.003 -0.003 0.25 0.01850.012 0.126 0.0210.002 -0.0075-0.0025-0.0075 0.125 0.006 -0.00450.12 -0.01-0.0035-0.015-0.006-0.014 0.125 0.002 0.001 0.068 0.003-0.006-0.0055-0.0075-0.0075 5 mM DTT

Dilution+ -0.5 0.07050.039 0.25 0.028 0.014 0.125 0.003 -0.0195 0.125 -0.006-0.003 These data indicate that IgEH~ proteins that have cysteine residues substituted into their sequence, thereby allowing the formation of inter-chain disulfide bonds, have a reduced ability to bind to the human FceRIa protein.

Example 2.
This Example describes the production and analysis of crystals of a glycosylation mutant of the Ce3/Ce4 domain of human IgE.
A. Construction of a IgE Fc-Ce3/Ce4 CHO mutant A new mutant IgE-Fc protein was created in which the sequence of the glycosylation sites in the IgE-Fc-region Ce3/Ce4 domain protein were altered in order to prevent glycosylation at these sites. The CHO mutant was created using polymerase chain reaction (PCR) mutagenesis as follows:
Using a nucleic acid molecule encoding the IgE Ce3/Ce4 domains of IgE (SEQ ID
NO:10) as a template, 5' nucleic acid molecule and 3' nucleic acid molecule were created in two separate PCR reactions. The 5' nucleic acid molecule was synthesized using the primers HIGEFCIb and N371Q. The primer HIGEFClb, which has the sequence 5' TAGGGCTACGTAGATTCCAACCCGAGAGG 3', (represented by SEQ ID N0:3) contains a Snag I restriction site and encodes an a portion of the Fc protein having an N-terminal sequence (following restriction digest with Sna BI) of VDSNPR with D
corresponding to D330 of the mature sequence. The primer N371Q, which has the sequence 5' ACTGGCTCGAGACCAGGTCAGCTGCACGGTCCCCTTGCTGGGT 3' (represented by SEQ ID N0:4), introduces unique Xho I and Pvu II sites and contains the mutation which changes the asparagine at position 371 to a glutamine. The 3' nucleic acid molecule was synthesized using primers N383Q and HIGEFC2B. Primer N383Q, which has the sequence 5' CCTGGTCTCGAGCCAGTGGGAAGCCTGTGCAACACTCCACCAGAAAGGAGGA
G 3' (represented by SEQ ID N0:5), introduces a unique Xho I restriction site and contains the mutation that changes the asparagine at position 383 to a glutamine. Primer HIGEFC2B, which has the sequence 5' TCTAGGCAGCGGCCGCTTATCATTTACCGGGATTTACAG 3' (represented by SEQ
ID N0:6), terminates the Fc sequence at Lys 547 and contains a Not I
restriction site.
The 5' and 3' nucleic acid molecules were generated using standard PCR
conditions, gel purified and then digested with the restriction enzymes Snag I and Xho I (5' fiagment ) or Not I and Xho I ( 3' fragment). The digested nucleic acid molecules were then ligated together at their Xho I sites to yield a nucleic acid molecule encoding the Ce3/Ce4 domains containing the glycosylation site mutations (represented by SEQ ID
N0:7).
Translation of the newly constructed nucleic acid molecule results in a protein (represented by SEQ ID N0:8) lacking glycosylation recognition sites at positions 371 and 383.
For expression in insect cells, the newly constructed nucleic acid molecule encoding the Ce3/Ce4 domains for the carbohydrate mutant was amplified using primers IgECABac and HIGEF2b. The primer IgECAbac, which has the sequence 5' TAGGGCGGATCCCTGTGCAGATTCGAACCCGAGAGGGGTGAGCG3' (represented by SEQ ID N0:9), contains a BamH I site for cloning the nucleic acid molecule behind a signal sequence in the expression vector pAcGP67A (Catalog Number 221220P, Becton Dickinson Pharmingen, Franklin Lakes, N.J.). The encoded sequence of the N-terminus of the mature (signal sequence cleaved) protein is ADPCAD
with C
corresponding to C328 of the mature IgE. Following amplification, the nucleic acid molecule was digested with BamH I and Not I, gel purified and ligated into the pAcGP67A vector.
B. Expression, purification and crystallization of the CHO mutant proteins The IgE-Fc CHO mutant protein was expressed, purified to homogeneity and crystallized. The expression, purification, crystallization, characterization and data collection and refinement of the mutant protein was performed as described in Example 1 and Example 2 of U.S. Patent Publication No. US-2001-0039479-A. Three new crystals were generated and data obtained from these crystals are shown in Table 2.
Table 2. Data for the CHO mutant IgE Protein Crystals S ace Groua b c Mol/as Resolution m Cr stal C2 158 108 50 102 1.5 2.3 l Cr stal2P21 66 99 77 97 2.0 2 .45 Crystal P21 (Big) ~ ~ 150 96 3.0 ~ _ 3 48 104 ~ _

2.8 ~~

The data collection and refinement statistics obtained from Crystal 1 are shown below in Table 3.
Statistics based on m10 bi50CH0 m25 bi5_m35 P+EBA.pdb Table 3: Data Collection and Refinement C2 (f5) (pH 4.6) Data Collection Statistics Source APS DND 5-ID
Wavelength (A) 1.008 Resolution (A) 30.0-2.30 (2.38 - 2.30)t Completeness 98.8% (89.8%)fi Unique reflections (Total) 36,675 (139,507) Average redundancy 3.8 (3.7)t <I/~I> 15.4 (2.4)t Rmerge 6.2% (41.3%)1 Refinement No. of Reflections (free)36,675 (1,866) Rwork~free 27.4/29.3 Atoms (Total) 5059 Protein Atoms 4909 Water Molecules 0 Carbohydrate Atoms 150 Average B factor Protein x59.6 AZ

RMS Deviations from Ideality Bond angles 1.33 °
Bond lengths 0.008 A
Ramachandran (~'F
Favored 86.5 %
Allowed 12.2 %
Generous 0.9 %
Disallowed 0.4 %
fi Values for the highest resolution shell are shown in parentheses Rmerge=EIh-I/EIII, where Ii is the intensity of an individual reflection and is the average intensity of that reflection.
RWOrufree= EIIFpI-IF~II/EIFPI, where F° is the calculated and FP is the observed structure factor amplitude. RWork and Rfree were calculated using the working set and test set reflections, respectively.
Cell a=158.8 b=108.5 c= 50.4 (3=102° [**These are Denzo ave (not scalepack) refined]
Refinement values based on m10 bi50CH0 m25 bi5_m35_p+EBA.pdb Total # residues = 627 1.5 dimers/asu (=1.5 Fc molecules/asu) The data collection and refinement statistics obtained from Crystal 2 are shown below in Table 4.
Statistics based on min300 c3l.pdb Table 4: Data Collection and Refinement P21 (f8) (pH 4.6) Data Collection Statistics Source APS DND 5-ID

Wavelength (A) 1.000 Resolution (A) 30.0-2.45 (2.54 - 2.45)t Completeness 98.2% (82.3%)~

Unique reflections 36,017 (128,258) (Total) Average redundancy 3.63 (2.3)x' <Il6I> 22.2 ( 3.35)t Rmerge 5.9% (24.1%)t Refinement No. of Reflections 34,123 (1,824) (free) Rwork~free 29.3/31.2 Atoms (Total) 6,345 Protein Atoms 6,345 Water Molecules 0 Carbohydrate Atoms 0 Average B factor Protein 48.3 Aa RMS Deviations from Ideality Bond angles 3.06 Bond lengths 0.03 A

Ramachandran (~,yr) Favored 85.7 %

Allowed 11.2 %

Generous 1.8 %

Disallowed 1.3 %

~ Values for the highest resolution shell are shown in parentheses R",erge=E~II-I/EIII, where I; is the intensity of an individual reflection and is the average intensity of that reflection.
Rw°rx~free= EI~FPI-IF°I~/~IFPI, where F° is the calculated and Fp is the observed structure factor amplitude. RW°r~ and Rfree were calculated using the working set and test set reflections, respectively. , Cell a=65.7 b= 99.6 c=77.9 (3=97.1 °
Refinement values based on min300 c3l.pdb Total # residues = 816 2 dimers/asu (= 2 Fc molecules/asu) The data collection and refinement statistics obtained from Crystal 3 are shown below in Table 5.
Statistics based on m200 bi14v3 bgl0 bd8 m250 BE new.pdb Table 5: Data Collection and Refinement P21 "BIG" (f7) (pIi 4.6) Data Collection Statistics Source APS DND 5-ID

Wavelength (A) 1.000 Resolution (A) 30.0-2.80 (2.90 - 2.80)t Completeness 98.9% (100%)t Unique reflections 36,906 (139,248) (Total) Average redundancy 3.8 (3.8)t <I/6I> 16.7 (4.9)t Rmerge 7.3% (54.1%)~

Refinement No. of Reflections 35,046 (1,860) (free) Rwork~free 31.3/36.0 Atoms (Total) 9,300 Protein Atoms 9,300 Water Molecules 0 Carbohydrate Atoms 0 Average B factor Protein 72.3 A2 RMS Deviations from Ideality Bond angles 1.41 Bond lengths 0.009 A

Ramachandran (~,~r) Favored 82.9 %

Allowed 13.9 %

Generous 2.5 %

Disallowed 0.6 %
fi Values for the highest resolution shell are shown in parentheses R,nerge=~~II-I/EIII, where I; is the intensity of an individual reflection and is the average intensity of that reflection.
Rwou~fuee= ~I~FPI-IF°I~/~IFpI, where F° is the calculated and Fp is the observed structure factor amplitude. RWOUx and Rfree were calculated using the working set and test set reflections, respectively.
Cell a=48.9 b=104.9 c=150.0 (3=96.2°
Refinement values based on m165 bi15v2 bgl0 bd28 m250 BE new.pdb Total # residues = 1,182

3 dimers/asu (= 3 Fc molecule/asu) C. Description of the IgE Fc-region Ce3/Ce4 domain mutant protein structure The new crystal forms reveal additional information on the IgE-Fc conformational change, showing that the C3 domains can adopt a variety of intermediate conformations between the open and closed forms. Interestingly, the C3 domains that are in the closed conformation are generally more similar and therefore probably more restricted in their conformational flexibility. In contrast, those C3 domains that are closer to the open conformation adopt a wider variety of side-side conformations, suggesting that there are fewer restrictions on the movements of the domains in the open configuration.
These differences may have an impact on drug design and binding to the different forms and could be important for docking experiments.
Analysis of the conformational ensemble revealed by the determination of these additional crystal forms of the IgE-Fc suggest how dynamic motions within the IgE-Fc may be coupled to receptor binding and dissociation. For example, conformational changes of the IgE-Fc are likely important to the microscopic steps in association and release from the receptor Binding Sites 1 and 2. In addition, analysis of the conformational ensemble suggests how interactions with the IgE Ce2 domain could be involved in restricting such conformational flexibility and influence the rates of binding and dissociation from the receptor. The range of motions and conformational arrangements of the Ce3 domains observed in these multiple crystal forms establish a set of preferred arrangements which restrict possible models and approaches to blocking IgE
binding to its receptor and to stimulating dissociation from the bound state.
While the various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications are adaptations are within the scope of the present invention, as set forth in the following claims.

SEQUENCE LISTING
<110> Jardetzky, Theodore S.
Wurzburg, Beth A.
<120> MUTANTS OF IgE PROTEINS AND USES THEREOF
<130> AL-11-C1-PCT
<140> not yet assigned <141> 2003-OB-01 <150> 60/319,446 <151> 2002-08-02 <150> 10/211,948 <151> 2002-08-O1 <160> 49 <170> PatentIn version 3.2 <210> 1 <211> 669 <212> DNA
<213> Homo sapiens <220>
<221> CDS
<222> (1)..(666) <400> 1 gcggat tgt gat tcc sac ccg aga ggg gtg agc gcc 48 ccc tac cta agc AlaAsp Cys Asp Ser Asn Pro Arg Gly Val Ser Ala Pro Tyr Leu Ser cggccc ccg ttc gac ctg ttc atc cgc aag tcg ccc .
agc acg atc acc 96 ArgPro Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Ser Thr Ile Thr tgtctg gtg gac ctg gca ccc agc aag ggg acc gtg 144 gtg aac ctg acc CysLeu Val Asp Leu Ala Pro Ser Lys Gly Thr Val Val Asn Leu Thr tggtcc gcc agt ggg aag cct gtg aac cac tcc acc 192 cgg aga aag gag TrpSer Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Arg Lys Glu gagaag cgc aat ggc acg tta acc gtc acg tcc acc 240 cag ctg ccg gtg GluLys Arg Asn Gly Thr Leu Thr Val Thr Ser Tlzt Gln Leu Pro Val ggcacc gac tgg atc gag ggg gag acc tac cag tgc 288 cga agg gtg acc GlyThr Asp Trp Ile Glu G1y Glu Thr Tyr Gln Cys Arg Arg Val Thr cacccc ctg ccc agg gcc ctc atg cgg tcc acg acc 336 cac aag acc agc HisPro Leu Pro Arg Ala Leu Met Arg Ser Thr Thr His Lys Thr Ser ggcccg get gcc ccg gaa gtc tat gcg ttt gcg acg 384 cgt ccg gag tgg GlyPro Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Arg Pro Glu Trp WO 2004/013158 PCT/i1S2003/024336 ccg ggg agc cgg gac aag cgc acc ctc gcc tgc ctg 432 atc cag aac ttc Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe atg cct gag gac atc tcg gtg cag tgg ctg cac aac 480 gag gtg cag ctc Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu ccg gac gcc cgg cac agc acg acg cag ccc cgc aag 528 acc aag ggc tcc Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Set ggc ttc ttc gtc ttc agc cgc ctg gag gtg acc agg 576 gcc gaa tgg gag Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu cag aaa gat gag ttc atc tgc cgt gca gtc cat gag 624 gca gcg agc ccc Gln Lys Asp Glu Phe Ile Cys Arg Ala Va1 His Glu Ala Ala Ser Pro tca cag acc gtc cag cga gcg gtg tct gta aat ccc 669 ggt aaa tga Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 2 <211> 222 <212> PRT
<213> Homo Sapiens <400> 2 A1a Asp Pro Cys Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu G1u Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Ireu Pro Val Gly Thr Arg Asp Trp Ile Glu G1y Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp WO 2004/013158 PCTlUS20031024336 Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly~Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Sex Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 3 <211> 29 <212> DNA
<213> Artificial sequence <220>
<223> Synthetic Primer <400> 3 tagggctacg tagattccaa cccgagagg 29 <210> 4 <211> 43 <212> DNA
<213> Artificial sequence <220>
<223> Synthetic Primer <400> 4 actggctcga gaccaggtca gctgcacggt ccccttgctg ggt 43 <210> 5 <211> 53 <212> DNA
<213> Artificial sequence <220>
<223> Synthetic Primer <400> 5 cctggtctcg agccagtggg aagcctgtgc aacactccac cagaaaggag gag 53 <210> 6 <211> 39 <212> DNA

<213> Artificial sequence <220>
<223> Synthetic Primer <400> 6 tctaggcagc ggccgcttat catttaccgg gatttacag 39 <210> 7 <211> 672 <212> DNA
<213> Homo Sapiens <220>
<221> CDS
<222> (1)._(672) <400> 7 gcg gat ccc gat tcc aac ccg aga ggg gtg agc 48 tgt gcg gcc tac cta Ala Asp Pro Asp Ser Asn Pro Arg Gly Val Ser Cys A1a Ala Tyr Leu agc cgg ccc ttc gac ctg ttc atc cgc aag tcg 96 agc ccg ccc acg atc Ser Arg Pro Phe Asp Leu Phe Ile Arg Lys 5er Ser Pro Pro Thr Ile acc tgt ctg gac ctg gca ccc agc aag ggg acc 144 gtg gtg gtg cag ctg Thr Cys Leu Asp Leu Ala Pro Ser Lys Gly Thr Val Val Val Gln Leu acc tgg tcc agt ggg aag cct gtg caa cac tcc 192 cgg gcc acc aga aag Thr Trp Ser 5er Gly Lys Pro Val Gln His Ser Arg A1a Thr Arg Lys gag gag aag aat ggc acg tta acc gtc acg tcc 240 cag cgc acc ctg ccg Glu Glu Lys Asn Gly Thr Leu Thr Val Thr Ser Gln Arg Thr Leu Pro gtg ggc acc tgg atc gag ggg gag acc tac cag 288 cga gac tgc agg gtg Val Gly Thr Ti-p Ile Glu Gly Glu Thr Tyr Gln Arg Asp Cys Arg Val acc cac ccc ccc agg gcc ctc atg cgg tcc acg 336 cac ctg acc aag acc Thr His Pro Pro Arg Ala Leu Met Arg Ser Thr His Leu Thr LyS Thr agc ggc ccg gcc ccg gas gtc tat gcg ttt gcg 384 cgt get acg ccg gag Ser Gly Pro Ala Pro Glu Val Tyr Ala Phe Ala Arg Ala Thr Pro Glu tgg ccg ggg gac aag cgc acc ctc gcc tgc ctg 432 agc cgg atc cag aac Trp Pro Gly Asp Lys Arg Thr Leu Ala Cys Leu Ser Arg Ile Gln Asn ttc atg cct atc tcg gtg cag tgg ctg cac aac 480 gag gac gag gtg cag Phe Met Pro Tle Ser Val Gln Trp Leu His Asn Glu Asp Glu Val Gln ctc ccg gac cac agc acg acg cag ccc cgc aag 528 gcc cgg acc aag ggc Leu Pro Asp His Ser Thr Thr Gln Pro Arg Lys Ala Arg Thr Lya Gly tcc ggc ttc ttc gtc ttc agc cgc ctg gag gtg acc agg gcc gaa tgg 576 5er Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp 180 185 . 190 gag cag aaa gat gag ttc atc tgc cgt gca gtc cat gag gca gcg agc 624 Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser ccc tca cag acc gtc cag cga gcg gtg tct gta aat ccc ggt aaa tga 672 Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 8 <211> 223 <212> PRT
<213> Homo Sapiens <400> 8 Ala Asp Pro Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu A1a Pro Ser Lys Gly Thr Val Gln Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Gln His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Va1 Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys I~:g Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 9 <211> 44 <212> DNA
<213> Artificial sequence <220>
<223> Synthetic Primer <400> 9 tagggcggat ccctgtgcag attcgaaccc gagaggggtg agcg 44 <210> 10 <211> 663 <212> DNA
<213> Homo sapiens <220>
<221> CDS
<222> (1)..(663) <400> 10 tgtgcggat tccaacccgagaggggtgagcgcctacctaagccggccc 48 CysAlaAsp SerAsnProArgGlyValSerAlaTyrLeuSerArgPro ageccgttc gacctgttcatccgcaagtcgcccacgatcacctgtctg 96 SerProPhe AspLeuPheIleArgLysSerProThrIleThrCysLeu gtggtggac ctggcacccagcaaggggaccgtgaacctgacctggtcc 144 ValValAsp LeuAlaProSerLysGlyThrValAsnLeuThrTrpSer cgggccagt gggaagcctgtgaaccactccaccagaaaggaggagaag 192 ArgAlaSer GlyLysProValAsnHisSerThrArgLysGluGluLys cagcgcaat ggcacgttaaccgtcacgtccaccctgccggtgggcacc 240 GlnArgAsn GlyThrLeuThrValThrSerThrLeuProValGlyThr 65 . 70 75 80 cgagactgg atcgagggggagacctaccagtgcagggtgacccacccc 288 ArgAspTrp IleG1uGlyGluThrTyrGlnCysArgValThrHisPro cacctgccc agggccctcatgcggtccacgaccaagaccagcggcccg 336 HisLeuPro ArgAlaLeuMetArgSerThrThrLysThrSerGlyPro cgt get gcc ccg gaa gtc tat gcg ttt gcg acg ccg gag tgg ccg ggg 384 Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly agc gacaagcgcaccctcgcctgcctgatccagaacttcatgcct 432 cgg Ser AspLysAxgThrLeuAlaCysLeuIleGlnAsnPheMetPro Arg gag atctcggtgcagtggctgcacaacgaggtgcagctcccggac 480 gac Glu IleSerValGlnTrpLeuHisAsnGluValGlnLeuProAsp Asp gcc cacagcacgacgcagccccgcaagaccaagggctccggcttc 528 cgg A1a HisSerThrThrGlnProArgLysThrLysGlySerGlyPhe Arg ttc ttcagccgcctggaggtgaccagggccgaatgggagcagaaa 576 gtc Phe PheSerArgLeuGluValThrArgAlaGluTrpG1uGlnLys Val 180~ 185 190 gat ttcatctgccgtgcagtccatgaggcagegagcccctcacag 624 gag Asp PheTleCysArgAlaValHisGluAlaAlaSerProSerGln Glu acc cagcgagcggtgtctgtaaatcccggtaaatga 663 gtc Thr GlnArgAlaValSerValAsnProGlyLya Val <210> 11 <211> 220 <212> PRT

<213> Homosapiens <400> 11 Cys Als Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn G1u Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr. Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 12 <211> 663 <212> DNA
<213> Homo sapiens <220>
<221> CDS
<222> (1)..(663) <400> 12 gcgtgtgattccaacccgagaggggtgagc gcctacctaagccggccc 48 AlaCysAspSerAsnProArgGlyValSer AlaTyrLeuSerArgPro agcccgttcgacctgttcatccgcaagtcg cccacgatcacctgtctg 96 SerProPheAspLeuPheileArgLysSer ProThrIleThrCysLeu gtggtggacctggcacccagcaaggggacc gtgaacctgacctggtcc 144 ValValAspLeuAlaProSerLysGlyThr ValAsnLeuThrTrpSer cgggccagtgggaagcctgtgaaccactcc aceagaaaggaggagaag 192 ArgAlaSerGlyLysProValAsnHisSer ThrArgLysGluGluLys cagcgcaatggcacgttaaccgtcacgtcc accctgccggtgggcaoc 240 GlnArgAsnGlyThrLeuThrValThrSer ThrLeuProValGlyThr cgagactggatcgagggggagacctaccag tgcagggtgacccacccc 288 ArgAspTrpIleGluGlyGluThrTyrGln CysArgValThrHisPro cacctgcccagggccctcatgcggtccacg accaagaccagcggcccg 336 HisLeuProArgAlaLeuMetArgSerThr ThrLysThrSerGlyPro Page cgt get gcc ecg gaa gtc tat gcg ttt gcg acg ccg gag tgg ccg ggg 384 Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly agc cgg gac aag cgc acc ctc gcc tgc ctg atc cag aac ttc atg cct 432 Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro l30 135 140 gag gac tcg gtg cag tgg ctg cac aac gag gtg cag 480 atc ctc ccg gac Glu Asp Sex Val Gln Trp Leu His Asn Glu Val Gln Ile Leu Pro Asp gc~ cgg agc acg acg cag ccc cgc aag acc aag ggc 528 cac tcc ggc ttc Ala Arg Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly His Ser Gly Phe ttc gtc agc cgc ctg gag gtg acc agg gcc gaa tgg 576 ttc gag cag aaa Phe Val Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Phe Glu Gln Lys gat gag atc tgc cgt gca gtc cat gag gca gcg agc 624 ttc ccc tca cag Asp Glu Ile Cys Arg Ala Val His Glu Ala Ala Ser Phe Pro Ser Gln acc gtc cga gcg gtg tct gta aat ccc ggt aaa tga 663 cag Thr Val Arg Ala Val Ser Val Asn Pro Gly Lys Gln 27.0 215 220 <210> 13 <211> 220 <212> PRT
<213> Homo sapiens <400> 13 Ala Cys Asp Ser Asn Pro Arg Gly Val Ser A1a Tyr Leu Ser Arg Pro Ser Pro Pha Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala 5er Pro 5er Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 14 <211> 663 <212> DNA
<213> Homo Sapiens <220>
<221> CDS
<222> (1)..(663) <400> 14 gcg gcg tgy tcc aac ccg aga ggg gtg agc gcc tac 48 cta agc cgg ccc Ala Ala Cys Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro agc ccg ttc gac ctg ttc atc cgc aag tcg ccc acg 96 atc acc tgt ctg Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu gtg gtg gac ctg gca ccc agc aag ggg acc gtg aac 144 ctg acc tgg tcc Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser cgg gcc agt ggg aag cct gtg aac cac tcc acc aga 192 aag gag gag aag Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys cag cgc aat ggc acg tta acc gtc acg tcc acc ctg 240 ccg gtg ggc acc Gln Arg Asn Gly Thr Leu Thr Val Thr Ser.Thr Leu Pro Val Gly Thr cga gac tgg atc gag ggg gag ace tac cag tgc agg 288 gtg acc cac ccc Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro cac cccagggccctcatgcggtccacgaccaagaccagcggcccg 336 ctg His ProArgAlaLeuMetArgSerThrThrLysThr5erGlyPro Leu cgt gccccggaagtctatgcgtttgcgacgccggagtggccgggg 384 get Arg AlaProGluValTyrAlaPheAlaThrProGluTrpProGly Ala agc gacaagcgcaccctcgcctgcctgatccagaacttcatgcct 432 cgg Ser AspLysArgThrLeuAlaCysLeuIleGlnAsnPheMetPro Arg gag atctcggtgcagtggctgcacaacgaggtgcagctcccggac 480 gac Glu IleSerValGlnTrpLeuHisAsnGluValGlnLeuProAsp Asp gcc cacagcacgacgcagccccgcaagaccaagggctccggcttc 528 cgg Ala HisSerThrThrGlnProArgLysThrLysGlySerGlyPhe Arg ttc ttcagccgcctggaggtgaccagggccgaatgggagcagaaa 576 gtc Phe Phe5erArgLeuGluValThrArgAlaGluTrpGluGlnLys Val gat ttcatctgccgtgcagtccatgaggcagcgagcccctcacag 624 gag Asp PheIleCysArgAlaValHisGluAlaA1aSerProSerGln Glu acc cagcgagcggtgtctgtaaatcccggtaaatga 663 gtc Thr G1nArgAlaVa1SerValAsnProGlyLys Val <210> 15 <211> 220 <212> PRT

<213> Homosapiens <400> 15 Ala Ala Cys Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro 1 5 . 10 15 Ser Pro Phe Asp Leu Phe 21e Arg Lys Ser Pro Thr I1e Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe I1e Cys Arg Ala Val His Glu Ala A1a Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 16 <211> 663 <212> DNA
<213> Homo Sapiens <220>
<221> CDS
<222> (1)..(663) <400> 16 gcg gcg gat tgy aac ccg aga ggg gtg agc gcc tac 48 cta agc cgg ccc Ala Ala Asp Cys Asn Pro Arg Gly Va1 Ser Ala Tyr Leu Ser Arg Pro agc ccg ttc gac ctg ttc atc cgc aag tcg ccc acg 96 atc acc tgt ctg Ser Pro Phe Asp Leu Phe Ile Arg Lys Sex Pro Thr Ile Thr Cys Leu gtg gtg gac ctg gca ccc agc aag ggg acc gtg aac 144 ctg acc tgg tcc Val Val Asp Leu A1a Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser cgg gcc agt ggg aag cct gtg aac cac tcc acc aga 192 aag gag gag aag Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Axg Lys Glu Glu Lys cag cgc aat ggc acg tta acc gtc acg tcC acc ctg 240 ccg gtg ggc acc Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr cgagactggatcgagggggagacctaccagtgcagggtgacccacccc 288 ArgAspTrpIleGluGlyGluThrTyrGlnCysArgValThrHisPro cacctgcccagggccctcatgcggtccacgaccaagaccagcggcccg 336 HisLeuProArgAlaLeuMetArgSerThrThrLysThrSerGlyPro cgtgetgccccggaagtctatgcgtttgcgacgccggagtggccgggg 384 ArgAlaAlaProGluValTyrAlaPheAlaThrProGluTrpProGly agccgggacaagcgcaccctcgcctgcctgatccagaacttcatgcct 432 SerArgAspLysArgThrLeuAlaCysLeuIleGlnAsnPheMetPro gaggacatctcggtgcagtggctgcacaacgaggtgcagctcccggac 480 GluAspIleSerValGlnTrpLeuHisAsnGluValGlnLeuProAsp gcccggcacagcacgacgcagccccgcaagaccaagggctccggcttc 528 AlaArgHisSerThrThrGlnProArgLysThrLysGlySerGlyPhe 165 170 ' 175 ttcgtcttcagccgcctggaggtgaccagggccgaatgggagcagaaa 576 PheValPheSerArgLeuGluValThrArgA1aGluTrpGluGlnLys gatgagttcatctgccgtgcagtccatgaggcagcgagcccctcacag 624 AspGluPheIleCysArgAlaValHisGluAlaAlaSerProSerGln accgtccagcgagcggtgtctgtaaatcccggtaaatga 663 ThrValGlnArgAlaValSerValAsnProGlyLys <210> 17 <211> 220 <212> PRT

<213> Homosapiens <400> 17 Ala Ala Asp Cys Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Va1 Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro 85 90 . 95 His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp =1e Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser G1y Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys 180 185 l90 Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 18 <211> 663 <212> DNA
<213> Homo Sapiens <220>
<221> CDS
<222> (1)..(663) <400> 18 gcggcg gattcctgy agaggggtgagcgcctacctaagccggCcc 48 ccg AlaAla AspSerCysProArgGlyValSerAlaTyrLeuSerArgPro agcccg ttcgacctgttcatccgcaagtcgcccacgateacctgtctg 96 SerPro PheAspLeuPheIleArgLysSerProThrIIeThrCysLeu gtggtg gacctggcacccagcaaggggaccgtgaacctgacctggtcc l44 ValVal AspLeuAlaProSerLysGlyThrValAsnLeuThrTrpSer cgggcc agtgggaagcctgtgaaccactccaccagaaaggaggagaag l92 ArgAla SerGlyLysProValAsnHisSerThrArgLysGluGluLys cag cgc aat ggc acg tta acc gtc acg tcc acc ctg ccg gtg ggc acc 240 Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr cga gac tgg atc gag ggg gag acc tac cag tgc agg 288 gtg acc cac ccc Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro cac ctg ccc agg gcc ctc atg cgg tcc acg acc aag 336 acc agc ggc ccg His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro cgt get gcc ccg gaa gtc tat gcg ttt gcg acg ccg 384 gag tgg ccg ggg Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly agc cgg gac aag cgc acc ctc gcc tgc ctg atc cag 432 aac ttc atg cct Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro 130 _ 135 140 gag gac atc tcg gtg cag tgg ctg cac aac gag gtg 480 cag ctc ccg gac Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val G1n Leu Pro Asp gcc cgg cac agc acg acg cag ccc cgc aag ace aag 528 ggc tcc ggc ttc Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe ttc gtc ttc agc cgc ctg gag gtg acc agg gcc gaa 576 tgg gag cag aaa Phe Val Phe Ser Arg Leu Glu Val Thr Arg Als Glu Trp Glu Gln Lys gat gag ttc atc tgc cgt gca gtc cat gag gca gcg 624 agc ccc tca cag Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln acc gtc cag cga gcg gtg tct gta aat ccc ggt aaa 663 tga Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 19 <211> 220 <212> PRT

<213> Homo Sapiens <400> 19 Ala Ala Asp Ser Cys Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys 50 . 55 60 Glri Arg Asn G1y Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Va1 Ser Val Asn Pro Gly Lys <210> 20 <211> 663 <212> DNA
<213> Homo Sapiens <220>
<221> CDS
<222> (1)..(663) <400> 20 gcg gcg gat tgyaga ggg gtg agc gcc tac cgg ccc 48 tcc aac cta agc Ala A1a Asp CysArg Gly Val Sex Ala Tyr Arg Pro Ser Asn Leu Ser agc ccg ttc ttcatc cgc aag tcg ccc acg tgt ctg .
gac ctg atc acc 96 Ser Pro Phe PheI1e Arg Lys Ser Pro Thr Cys Leu Asp Leu Ile Thr gtg gtg gac cccagc aag ggg acc gtg aac tgg tcc 144 ctg gca ctg acc Val Val Asp ProSer Lys Gly Thr Val Asn Trp Ser Leu Ala Leu Thr cgg gcc agt cctgtg aac cac tcc acc aga gag aag 192 ggg aag aag gag Arg Ala Ser ProVal Asn His Ser Thr Arg Glu Lys Gly Lys Lys Glu eag cgc aat ggc acg tta acc gtc acg tcc ace ctg 240 ccg gtg ggc acc Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr cga gac tgg atc gag ggg gag acc tac cag tgc agg 288 gtg acc cac ccc Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro cac ctg ccc agg gcc ctc atg cgg tcc acg acc aag 336 acc agc ggc ccg His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro cgt get gcc ccg gaa gtc tat gcg ttt gcg acg ccg 384 gag tgg ccg ggg Arg Ala Ala Pro G1u Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly agc cgg gac aag cgc acc ctc gcc tgc ctg atc cag 432 aac ttc atg cct Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro 130 l35 140 gag gac atc tcg gtg cag tgg ctg cac aac gag gtg 480 cag ctc ccg gac Glu Asp Ile Ser Va1 Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp gcc cgg cac agc acg acg cag ccc cgc aag acc aag 528 ggc tcc ggc ttc Ala Arg His Ser Thr -Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe 165 ' 170 175 ttc gtc ttc agc cgc ctg gag gtg acc agg gcc gaa 576 tgg gag cag aaa Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu GIn Lys gat gag ttC atc tgc cgt gca gtc cat gag gca gcg 624 agc ccc tca cag Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln acc gtc cag cga gcg gtg tct gta aat ccc ggt aaa 663 tga Thr Val Gln Arg Ala Va1 Ser Val Asn Pro Gly Lys <210> 21 <211> 220 <212> PRT
<213> Homo sapiens <400> 21 Ala Ala Asp Ser Asn Cys Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu A1a Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu A1a Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys 210 . 215 220 <210> 22 <211> 663 <212> DNA
<213> Homo Sapiens <220>
<221> CDS
<222> (1)..(663) <400> 22 gcg gcg gat tcc aac ccg tgy ggg gtg agc gcc tac cta agc cgg ccc 48 Ala Ala Asp Ser Asn Pro Cys Gly Val Ser Ala Tyr Leu Ser Arg Pro 10 l5 agc ccg ttc gac ctg ttc atc cgc aag tcg ccc acg atc acc tgt ctg 96 Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu 20 , 25 30 gtg gtg gac ctg gca ccc agc aag ggg acc gtg aac ctg acc tgg tcc 144 Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser cgggccagt gggaagcct gtgaaccac tccaccaga aaggaggag aag 192 ArgAlaSer GlyLysPro ValAsnHis SerThrArg LysGluGlu Lys cagcgcaat ggcacgtta accgtcaog tccaccctg ccggtgggc acc 240 GlnArgAsn GlyThrLeu ThrValThr SerThrLeu ProValGly Thr cgagactgg atcgagggg gagacctac cagtgcagg gtgacccac ccc 288 ArgAspTrp IleGluGly GluThrTyr GlnCysArg ValThrHis Pro cacctgccc agggccctc atgcggtcc acgaccaag accagcggc ccg 336 HisLeuPro ArgAlaLeu MetArgSer ThrThrLys ThrSerGly Pro cgtgetgcc ccggaagtc tatgcgttt gcgacgccg gagtggccg ggg 384 ArgAlaAla ProGluVal TyrAlaPhe AlaThrPro GluTrpPro Gly agccgggac aagcgcacc ctcgcctgc ctgatccag aacttcatg cct 432 SerArgAsp LysArgThr LeuAlaCys LeuIleGln AsnPheMet Pro gaggacatc tcggtgcag tggctgcac aacgaggtg cagctcccg gac 480 GluAspIle SerValGln TrpLeuHis AsnGluVal GlnLeuPro Asp gcccggcac agcacgacg cagccccgc aagaccaag ggctccggc ttc 528 AlaArgHis SerThrThr GlnProArg LysThrLys GlySerGly Phe ttcgtcttc agccgcctg gaggtgacc agggccgaa tgggagcag aaa 576 PheValPhe SerArgLeu GluValThr ArgAlaGlu TrpGluGln Lys gatgagttc atctgccgt gcagtccat gaggcagcg agcccctca cag 624 AspGluPhe IleCysArg AlaValHis GluAlaAla SerProSer Gln accgtccag cgagcggtg tctgtaaat cccggtaaa tga 663 ThrValGln ArgA1aVal SerValAsn ProGlyLys <210> 23 <211> 220 <212> PRT

<213> HomoSapiens <400> 23 Ala Ala Asp Ser Asn Pro Cys Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Va1 Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser Va1 Asn Pro Gly Lys <210> 24 <211> 663 <212> DNA
<213> Homo sapiens <220>
<22l> CDS
<222> (1)..(663) <400> 24 gcg gcg gat tcc aac ccg aga tgy gtg agc gcc tac cta agc cgg ccc 48 Ala Ala Asp Ser Asn Pro Arg Cys Val Ser Ala Tyr Leu Ser Arg Pro agc ccg ttc gac ctg ttc atc cgc aag tcg ccc acg atc aco tgt ctg 96 Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu gtggtg gacctggca cccagcaag gggaccgtgaac ctgacc tggtcc 144 ValVal AspLeuAla ProSerLys GlyThrValAsn LeuThr TrpSer cgggcc agtgggaag cctgtgaac cactccaccaga aaggag gagaag 192 ArgAla SerGlyLys ProValAsn HisSerThrArg LysGlu GluLys cagcgc aatggcacg ttaaccgtc acgtccaccctg ccggtg ggcacc 240 GlnArg AsnGlyThr LeuThrVal ThrSerThrLeu ProVal GlyThr cgagac tggatcgag ggggagacc taccagtgcagg gtgacc cacccc 288 ArgAsp TrpIleGlu GlyG1uThr TyrGlnCysArg ValThr HisPro cacctg CCCagggCC CtCatgcgg tccacgaccaag accagc ggcccg 336 HisLeu ProArgAla LeuMetArg SerThrThrLys ThrSer GlyPro cgtget gccccggaa gtctatgcg tttgcgacgccg gagtgg ccgggg 384 ArgAla AlaProGlu ValTyrAla PheAlaThrPro GluTrp ProGly agccgg gacaagCgC aCCCtCgcc tgcctgatccag aacttc atgcct 432 SerArg AspLysArg ThrLeuAla CysLeuIleGln AsnPhe MetPro gaggac atctcggtg cagtggctg cacaacgaggtg cagctc ccggac 480 GluAsp IleSerVal GlnTrpLeu HisAsnGluVal GlnLeu ProAsp gcccgg cacagcacg acgcagccc cgcaagaccaag ggctcc ggcttc 528 AlaArg HisSerThr ThrGlnPro ArgLysThrLys GlySer GlyPhe ttcgtc ttcagccgc ctggaggtg accagggccgaa tgggag cagaaa 576 PheVal PheSerArg LeuGluVal ThrArgAlaGlu TrpGlu GlnLys gatgag ttcatctgc cgtgcagtc catgaggcagcg agcccc tcacag 624 AspGlu PheIleCys ArgAlaVal HisGluAlaAla SerPro SerGln accgtc cagcgagcg gtgtctgta aatcccggtaaa tga 663 ThrVal GlnArgAla ValSerVal AsnProGlyLys <210> 25 <211> 220 <212> PRT

<213> HomoSapiens <400> 25 Ala Ala Asp Ser Asn Pro Arg Cys Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Va1 Phe Ser Arg Leu Glu Val Thr Arg A1a Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His G1u Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro G1y Lys <210> 26 <211> 663 <212> DNA
<213> Homo sapiens <220>
<221> CDS
<222> (1)..(663) <400> 26 gcg gcg gat tcc aac ccg aga ggg tgy agc gcc tac cta agc cgg ccc 48 Ala Ala Asp Ser Asn Pro Arg Gly Cys Ser Ala Tyr Leu Ser Arg Pro agc ccg ttc gac ctg ttc atc cgc aag tcg ccc acg atc acc tgt ctg 96 Ser ProPheAspLeu PheIle ArgLysSerPro ThrIleThr CysLeu gtg gtggacctggca cccagc aaggggaccgtg aacctgacc tggtcc 144 Val ValAspLeuAla ProSer LysGlyThrVa1 AsnLeuThr TrpSer cgg gccagtgggaag cctgtg aaccactccacc agaaaggag gagaag 192 Arg AlaSerGlyLys ProVal AsnHisSerThr ArgLysGlu GluLys cag cgcaatggcacg ttaacc gtcacgtccacc ctgccggtg ggcacc 240 Gln ArgAsnGlyThr LeuThr ValThrSerThr LeuProVal GlyThr cga gactggatcgag ggggag acctaccagtgc agggtgacc cacccc 288 Arg AspTrpIleGlu GlyGlu ThrTyrGlnCys ArgValThr HisPro g5 90 95 cac ctgcccagggcc ctcatg cggtccacgacc aagaccagc ggcccg 336 His LeuProArgAla LeuMet ArgSerThrThr LysThrSer GlyPro cgt getgccccggaa gtctat gcgtttgcgacg ccggagtgg ccgggg 384 Arg AlaAlaProGlu ValTyr AlaPheAlaThr ProGluTrp ProGly agc cgggacaagcgc accctc gcctgcctgatc cagaacttc atgcct 432 Ser ArgAspLysArg ThrLeu AlaCysLeuIle GlnAsnPhe MetPro gag gacatctcggtg cagtgg ctgcacaacgag gtgcagctc ccggac 480 Glu AspIleSerVal GlnTrp LeuHisAsnGlu ValGlnLeu ProAsp gcc cggcacagcacg acgcag ccccgoaagacc aagggctcc ggcttc 528 Ala ArgHisSerThr ThrGln ProArgLysThr LysGlySer GlyPhe ttc gtcttcagccgc ctggag gtgaccagggcc gaatgggag cagaaa 576 Phe ValPheSerArg LeuGlu ValThrArgAla GluTrpGlu GlnLys gat gagttcatctgc cgtgca gtccatgaggca gcgagcccc tcacag 624 Asp GluPheIleCys ArgAla ValHisGluAla AlaSerPro SerGln acc gtccagcgagcg gtgtct gtaaatcccggt aaatga 663 Thr ValGlnArgAla ValSer ValAsnProGly Lys <21 0> 27 <21 1> 220 <21 2> PRT

<21 3> Homosapiens <400> 27 Ala Ala Asp Ser Asn Pro Arg Gly Cys Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg~Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Va1 Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pr_o Glu Trp Pro G1y Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Va1 His Glu Ala A1a Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys <210> 28 <211> 44 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(43) <400> 28 t agg gcg gat ccc get gca gat tcg aac ccg aga ggg gtg agc g 44 Arg Ala Asp Pro Ala Ala Asp Ser Asn Pro Arg Gly Val Ser <210> 29 <211> 14 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 29 Arg Ala Asp Pro Ala Ala Asp Ser Asn Pro Arg Gly Val Ser <210> 30 <211> 44 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(43) <400> 30 t agg gcg gat ccc tct gca gat tcg aac ccg aga ggg gtg agc g 44 Arg Ala Asp Pro Ser Ala Asp Ser Asn Pro Arg Gly Val Ser <210> 31 <211> 14 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 31 Arg Ala Asp Pro Ser Ala Asp Ser Asn Pro Arg Gly Val Ser <210> 32 <211> 42 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS

<222> (2)..(40) <400> 32 t agg gcg gat ccc tgt gcg gat tcg aac ccg aga ggg gtg ag 42 Arg Ala Asp Pro Cys Ala Asp Ser Asn Pro Arg Gly Val <210> 33 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 33 Arg Ala Asp Pro Cys Ala Asp Ser Asn Pro Arg Gly Val <210> 34 <211> 42 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(40) <400> 34 t agg gcg gat ccc gcg tgt gat tcg aac ccg aga ggg gtg ag 42 Arg Ala Asp Pro Ala Cys Asp Ser Asn Pro Arg Gly Val <210> 35 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 35 Arg Ala Asp Pro Ala Cys Asp Ser Asn Pro Arg Gly Val <210> 36 <211> 42 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(40) <400> 36 t agg gcg gat ccc gcg gcg tgt tcg aac ccg aga ggg gtg ag 42 Arg Ala Asp Pro Ala Ala Cys Ser Asn Pro Arg Gly Val <210> 37 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 37 Arg Ala Asp Pro Ala Ala Cys Ser Asn Pro Arg Gly Val <210> 38 <211> 42 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(40) <400> 38 t agg gcg gat ccc gcg gcg gat tgt aac ccg aga ggg gtg ag 42 Arg Ala Asp Pro Ala Ala Asp Cys Asn Pro Arg Gly Val <210> 39 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 39 Arg Ala Asp Pro Ala Ala Asp Cys Asn Pro Arg Gly Val <210> 40 <211> 42 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(40) <400> 40 t agg gcg gat CCC gcg gcg gat tcg tgt ccg aga ggg gtg ag 42 Arg Ala Asp Pro Ala Ala Asp Ser Cys Pro Arg Gly Val <210> 41 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 41 Arg Ala Asp Pro Ala Ala Asp Ser Cys Pro Arg Gly Val <210> 42 <211> 42 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(40) <400> 42 t agg gcg gat ccc gcg gcg gat tcg aac tgt aga ggg gtg ag 42 Arg Ala Asp Pro Ala Ala Asp Ser Asn Cys Arg Gly Val <210> 43 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 43 Arg Ala Asp Pro Ala Ala Asp Ser Asn Cys Arg Gly Val <210> 44 <211> 42 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(40) <400> 44 t agg gcg gat ccc gcg gcg gat tcg aac ccg tgt ggg gtg ag 42 Arg Ala Asp Pro Ala Ala Asp Ser Asn Pro Cys Gly Val <210> 45 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 45 Arg Ala Asp Pro Ala A1a Asp Sex Asn Pro Cys Gly Va1 <210> 46 <211> 42 <212> DNA
<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(40) <400> 46 t agg gcg gat ccc gcg gcg gat tcg aac ccg aga tgt gtg ag 42 Arg Ala Asp Pro Ala Ala Asp Ser Asn Pro Arg Cys Val <210> 47 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 47 Arg Ala Asp Pro Ala Ala Asp Ser Asn Pro Arg Cys Val <210> 48 <211> 42 <212> DNA

<213> Artificial <220>
<223> Synthetic Primer <220>
<221> CDS
<222> (2)..(40) <400> 48 t agg gcg gat ccc gcg gcg gat tcg aac ccg aga ggg tgt ag 42 Arg Ala Asp Pro Ala Ala Asp Ser Asn Pro Arg Gly Cys <210> 49 <211> 13 <212> PRT
<213> Artificial <220>
<223> Synthetic Primer <400> 49 Arg Ala Asp Pro Ala A1a Asp Ser Asn Pro Arg Gly Cys

Claims

What is claimed is:

1. An isolated mutant IgE protein, wherein mutant IgE HC proteins of said mutant IgE protein have reduced spatial mobility compared to the spatial mobility of unmodified IgE HC proteins in an unmodified IgE protein, wherein said unmodified IgE HC's comprise the amino acid sequence of SEQ ID NO:11.

2. The isolated mutant IgE protein of Claim 1, wherein said mutant IgE
protein is constrained to the open conformation or the closed conformation.

3. The isolated mutant IgE protein of Claim 1, wherein the N-terminal amino-acids residues of the C~3 domains of said mutant IgE HC proteins are unable to obtain an inter-residue distance of 23.ANG. or more.

4. The isolated mutant IgE protein of Claim 1, wherein the N-terminal amino-acids residues of the C~3 domains of said mutant IgE HC proteins have a fixed, inter-residue distance of between about 13 .ANG. and less than 23 .ANG..

5. The isolated mutant IgE protein of Claim 1, wherein said mutant IgE
protein is constrained in a conformation in which the N-terminal amino-acids residues of the C~3 domains of said IgE HC proteins have an inter-residue distance selected from the group consisting of a distance of about 13.ANG., a distance of about 14.ANG., a distance of about 15.ANG., a distance of about 16.ANG., a distance of about 17.ANG., a distance of about 18.ANG., a distance of about 19.ANG., a distance of about 20.ANG., a distance of about 21.ANG. a distance of about 22.ANG. or a distance of between about 22 .ANG. and less than 23.ANG..

6. The isolated mutant IgE protein of Claim 1, wherein said mutant IgE
protein comprises a IgE HC protein that comprises an amino acid sequence at least about 80% identical to SEQ ID NO:11, wherein the amino acid in said protein corresponding to position 2, 3, 4, 5, 6, 7, 8 or 9 or SEQ ID NO:11 is a cysteine or methionine.

7. The isolated mutant IgE protein of Claim 6, wherein said mutant IgE
protein binds to an antibody raised against an IgE protein comprising an unmodified IgE HC comprising the amino acid sequence of SEQ ID NO:11.

8. The isolated mutant IgE protein of Claim 1, wherein said mutant IgE HC
proteins comprise an amino acid sequence selected from the group consisting of SEQ ID
NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27.

9. An isolated nucleic acid molecule comprising a nucleic acid sequence at least about 80% identical to SEQ ID NO:10, wherein the codon in said nucleic acid sequence corresponding to nucleotides 4-6, 7-9, 10-12, 13-15, 16-18, 19-21, 22-24, or 25-27 of SEQ ID NO:10 encodes a cysteine or a methionine.

10. The isolated nucleic acid molecule of Claim 9, wherein said nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of:
(a) a nucleic acid sequence at least about 90% identical to SEQ ID
NO:10, wherein the codon at nucleotides 4-6 of said nucleic acid sequence encodes a cysteine or a methionine;
(b) a nucleic acid sequence at least about 90% identical to SEQ ID
NO:10, wherein the codon at nucleotides 7-9 of said nucleic acid sequence encodes a cysteine or a methionine;
(c) a nucleic acid sequence at least about 90% identical to SEQ ID
NO:10, wherein the codon at nucleotides 10-12 of said nucleic acid sequence encodes a cysteine or a methionine;
(d) a nucleic acid sequence at least about 90% identical to SEQ ID
NO:10, wherein the codon at nucleotides 13-15 of said nucleic acid sequence encodes a cysteine or a methionine;
(e) a nucleic acid sequence at least about 90% identical to SEQ ID
NO:10, wherein the codon at nucleotides 16-18 of said nucleic acid sequence encodes a cysteine or a methionine;
(f) a nucleic acid sequence at least about 90% identical to SEQ ID
NO:10, wherein the codon at nucleotides 19-21 of said nucleic acid sequence encodes a cysteine or a methionine;
(g) a nucleic acid sequence at least about 90% identical to SEQ ID
NO:10, wherein the codon at nucleotides 22-24 of said nucleic acid sequence encodes a cysteine or a methionine; and (h) a nucleic acid sequence at least about 90% identical to SEQ ID
NO:10, wherein the codon at nucleotides 25-27 of said nucleic acid sequence encodes a cysteine or a methionine.

11. The isolated nucleic acid molecule of Claim 9, wherein said nucleic acid sequence encodes a protein having an amino acid sequence at least about 80%
identical to SEQ ID NO:11, wherein the amino acid in said protein corresponding to position 2, 3, 4, 5, 6, 7, 8 or 9 or SEQ ID NO:11 is a cysteine or methionine and wherein said protein binds an antibody raised against a protein having the amino acid sequence of SEQ ID
NO:11.

12. The isolated nucleic acid molecule of Claim 9, wherein said nucleic acid ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID
NO:26.

13. An isolated protein having an amino acid sequence at least about 80%
identical to SEQ ID NO:11, wherein the amino acid in said protein corresponding to position 2, 3, 4, 5, 6, 7, 8 or 9 or SEQ ID NO:11 is a cysteine or methionine and wherein said protein binds to an antibody raised against a protein having the amino acid sequence of SEQ ID NO:11.

14. The isolated protein of Claim 13, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) an amino acid sequence at least about 90% identical to SEQ ID
NO:11, wherein the amino acid at position 2 of such amino acid sequence is a cysteine or a methionine;
(b) an amino acid sequence at least about 90% identical to SEQ ID
NO:11, wherein the amino acid at position 3 of such amino acid sequence is a cysteine or a methionine;
(c) an amino acid sequence at least about 90% identical to SEQ ID
NO:11, wherein the amino acid at position 4 of such amino acid sequence is a cysteine or a methionine;
(d) an amino acid sequence at least about 90% identical to SEQ ID
NO:11, wherein the amino acid at position 5 of such amino acid sequence is a cysteine or a methionine;
(e) an amino acid sequence at least about 90% identical to SEQ ID
NO:11, wherein the amino acid at position 6 of such amino acid sequence is a cysteine or a methionine;
(f) an amino acid sequence at least about 90% identical to SEQ ID
NO:11, wherein the amino acid at position 7 of such amino acid sequence is a cysteine or a methionine;

(g) an amino acid sequence at least about 90% identical to SEQ ID
NO:11, wherein the amino acid at position 8 of such amino acid sequence is a cysteine or a methionine; and (h) an amino acid sequence at least about 90% identical to SEQ ID
NO:11, wherein the amino acid at position 9 of such amino acid sequence is a cysteine or a methionine.

15. The isolated protein of Claim 13, wherein said protein comprises an amino acid sequence selected from SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID
NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:17.

16. A method selected from the group consisting of:
(a) a method to identify a compound that inhibits the binding of IgE to a Fc.epsilon.RI, said method comprising:
(i) contacting an isolated mutant IgE protein of Claim 1 or an isolated protein of Claim 13 with a putative inhibitory compound in the presence of a Fc.epsilon.RI or Fc.epsilon.RI.alpha. protein; and (ii) determining if said putative inhibitory compound inhibits the binding of said mutant IgE protein of Claim 1 or said isolated protein of Claim 13 to said Fc.epsilon.RI or Fc.epsilon.RI.alpha. protein; and (b) a method to identify a compound that binds to IgE either in or resulting in a closed conformation, said method comprising:
(i) contacting an isolated mutant IgE protein of Claim 1 or an isolated protein of Claim 13 with a putative inhibitory compound in the presence of a Fc.epsilon.RI or Fc.epsilon.RI.alpha. protein; and (ii) determining if said putative inhibitory compound binds to said mutant IgE protein of Claim 1 or said isolated protein of Claim 13.

17. The method of Claim 16, wherein said mutated IgE molecule comprises IgE HC's comprising an amino acid sequence at least about 90% identical to SEQ
ID
NO:11, wherein the amino acid in said protein corresponding to position 2,3 ,4, 5, 6, 7, 8 or 9 or SEQ ID NO:11 is a cysteine or methionine and wherein said protein binds an antibody raised against a protein having the amino acid sequence of SEQ ID
NO:11.

18. An isolated compound that inhibits the binding of IgE to an Fc.epsilon.RI, wherein said compound is identified by the method of Claim 16.

19. The isolated compound of Claim 18, wherein said compound does not bind the open form of IgE.

20. A composition comprising the compound of Claim 18 and an excipient.

21. A method to protect an animal from a disease mediated by IgE, said method comprising administering a composition of Claim 20.

22. A kit comprising an isolated mutant IgE protein of Claim 1 or an isolated protein of Claim 13 and a means to determine if a compound binds to said isolated mutant IgE protein of Claim 1 or said isolated protein of Claim 13.